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INTRODUCTION: Sarcopenia is a loss of muscle function and muscle mass which 
frequently occurs among the oldest-old adult population (aged 85+ years). The analysis 
of accelerometer-determined physical behavior volumes and patterns of oldest-old adults 
might provide novel insights into the associations with sarcopenia and its components. 
METHODS: A total of 145 participants in the primary sample and 87 participants in the 
subsample with a mean age of 88.2 (2.5) years from the Health, Aging, and Body 
Composition study cohort provided cross-sectional data of handgrip strength, 
appendicular lean mass, gait speed, and accelerometry. Probable, confirmed, and severe 
sarcopenia were assessed based on the revised definition of the European Working Group 
on Sarcopenia in Older People 2. Binomial logistic and multivariate linear regression 
models as well as dose-response analyses were applied and adjusted for demographics, 
accelerometer wear time, lifestyle factors, and chronic health conditions. RESULTS: 
Oldest-old adults with higher total volumes of moderate to vigorous physical activity 
(MVPA) (OR=0.74, 95% CI 0.62 to 0.89) showed a lower likelihood for a probable 
sarcopenic condition in the primary sample. Likewise, patterns of higher accumulated 
vii 
time spent in MVPA bouts of less than 10 minutes (OR=0.78, 95% CI 0.64 to 0.95) and 
MVPA bouts of at least 10 minutes (OR=0.78, 95% CI 0.63 to 0.98) were also related 
with lower odds of probable sarcopenia. A 2.1 times (95% CI 1.01 to 4.35) higher 
likelihood for confirmed sarcopenia was observed among participants who spent 60 
minutes more per day in sedentary behavior (SB). Furthermore, 2.9 times (95% CI 1.05 
to 8.02) greater odds of severe sarcopenia were identified following each 0.1 higher 
active-to-sedentary transition probability (ASTP). Focusing on individual sarcopenic 
components, higher total activity counts, higher MVPA, higher light intensity physical 
activity (LIPA), lower SB, and lower ASTP were related with better gait speed. 
CONCLUSION: The total volume of MVPA, whether accumulated in short sporadic 
bouts or prolonged bouts, was associated with lower odds of probable sarcopenia. Higher 
LIPA, lower SB, and a less fragmented activity pattern might also be related with a lower 
likelihood of sarcopenia status and better physical performance among oldest-old adults.  
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Steady age-related decreases in muscle strength, muscle mass, and various 
physical performance measures occur simultaneously.1 This progressive and generalized 
loss of muscle function and mass is recognized as sarcopenia which is associated with 
diminished functional ability, poor quality of life, greater fall-related injuries, more 
frailty, and increased all-cause mortality among older adults.2–4 Sarcopenia affects more 
than 50 million people today and will impair more than 200 million people in the 
upcoming 40 years.5 In 2014, the global economic burden was estimated at USD $40.4 
billion from this skeletal muscle disorder.6  
The prevalence of sarcopenia and the related economic burden are expected to 
rise substantially in the foreseeable future due to the rapid global increase in the number 
of people aged 65 and older.1 In this context, the oldest-old adult population (aged 80-85 
years and older) demonstrate the highest growth rate which is anticipated to expand 
threefold between 2015 and 2050.7 This increasing proportion of older individuals can be 
explained by improved living conditions and advancing medical care.3 
The modifiable characteristics of physical behavior may include huge 
opportunities to reduce the prevalence of sarcopenia in the community. Consequently, the 
purpose of this thesis is to evaluate the associations of various physical behavior metrics 
with sarcopenia and its components among oldest-old adults. 
 
2 
1.2 Past and Present Definition of Sarcopenia 
The term sarcopenia was coined by Rosenberg in 1988 by combining the Greek 
words “sarx” which means “flesh” and “penia” which means “deficiency” to describe the 
paucity of muscle tissue often observed in older adults.8 Based on this definition, 
Baumgartner et al.9 developed the first epidemiological approach in 1998 to estimate the 
prevalence of sarcopenia by the application of an anthropometric equation in which the 
appendicular skeletal muscle mass was computed and evaluated. Soon after, researchers 
ascertained that muscle quantity alone was not pivotal as a parameter of adverse events 
and poor health outcomes.10 In 2010, the initial sarcopenia definition on the basis of low 
muscle mass was extended by adding muscle strength and physical performance.10 This 
move imposed by the European Working Group on Sarcopenia in Older People 
(EWGSOP) in 2010 was supported within the field of geriatrics.11 Just 28 years after its 
first terminological appearance, sarcopenia was formally recognized as a muscle disease 
by the World Health Organization in 2016 with its own International Classification of 
Disease, Tenth Revision, Clinical Modification code.12 
Between then and now, the interest on sarcopenia has exponentially grown in the 
scientific community.8 Classifying this geriatric condition as a disease has allowed 
physicians to run diagnostics and researchers to investigate an officially accepted health 
outcome.13 After defining sarcopenia by measures of muscle strength, muscle mass, and 
physical performance in 2010,10 several other definitions, namely the International 
Working Group on Sarcopenia in 2011,14 the Asian Working Group for Sarcopenia 
(AWGS) in 2014 and its updated version in 2019,15,16 the Foundation for the National 
Institutes of Health (FNIH) in 2014,17 and the revised definition of the European Working 
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Group on Sarcopenia in Older People 2 (EWGSOP2) in 2019,18 were developed with 
differences in their methodological approach.19 These operational dissimilarities are also 
based on racial and ethnic differences in body composition and grip strength.20 As a 
consequence, epidemiological prevalence studies vary substantially and depend on the 
definition used.20 For instance, lower estimates of sarcopenia are usually stated in studies 
which included measures of muscle function or physical performance in addition to 
muscle mass.21 Likewise, differences in participant age, applied muscle mass cut points, 
and the utilization of dual-energy X-ray absorptiometry (DXA) versus bioelectrical 
impedance analysis (BIA) may cause substantial study outcome deviations.21 This highly 
diverse application of definitions results in diagnosis rates of 1-29% in community-
dwelling populations and of 14-33% among residents living in long-term care facilities.19 
Another systematic review and meta-analysis found that the prevalence of sarcopenia was 
between 24-40% for single measure definitions and 10-19% by employing combined 
definitions.21  
At this point, the most used and cited definition is the one presented by the 
EWGSOP.10 Members of the EWGSOP revised their definition of sarcopenia and created 
the EWGSOP2 a few years later.18 Disparities between the EWGSOP and the modified 
EWGSOP2 are obvious due to alterations of cut-off values for determining low muscle 
strength and low muscle mass measures.22 These changes have shown substantial 
deviations in the prevalence rate of investigated populations.22 Nevertheless, EWGSOP2 
is the only definition endorsed and supported by a range of international scientific 
societies such as the AWGS, the European Geriatric Medicine Society, the European 
Society for Clinical Nutrition and Metabolism, the European Society for Clinical and 
4 
Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, 
International Osteoporosis Foundation, and International Association of Gerontology and 
Geriatrics European Region for research and clinical practice.18 
Table 1: EWGSOP2 sarcopenia cut-off values applied in our analyses 
Test Measurement tool Cut-off points  for men 
Cut-off points  
for women 
EWGSOP2 sarcopenia cut-off points for low muscle strength 
Grip strength Isometric handheld dynamometer <27 kg <16 kg 
EWGSOP2 sarcopenia cut-off points for low muscle mass 
Appendicular lean mass DXA <20 kg <15 kg 
EWGSOP2 sarcopenia cut-off points for low physical performance 
Gait speed 20-meter course ≤0.8 m/s 
 
The definition of EWGSOP2, which will be applied in our study, identifies 
probable, confirmed, or severe sarcopenia. In this regard, the detection of low muscle 
strength evaluated by a calibrated handgrip dynamometer (grip strength: <27 kg for men 
and <16 kg for women) predicts a probable sarcopenia diagnosis.18 This diagnosis can be 
confirmed after the observation of low muscle mass by using body composition measures 
(i.e., appendicular lean mass: <20 kg for men and <15 kg for women).18 Furthermore, low 
physical performance measures, which can be assessed by a variety of tests (i.e., gait 
speed: ≤0.8 m/s), provide information on the severity of sarcopenia.18 A severe 
sarcopenia diagnosis will be determined when all three sarcopenia-relevant indicators, 
including muscle strength, muscle mass, and physical performance, show measures 
below the specified cut-off points.18 All sarcopenic parameters and their cut-off values 
are illustrated in Table 1.  
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1.3 Muscle Strength and Muscle Mass Change across the Lifespan 
A considerable amount of evidence regarding the variation of muscle strength and 
muscle mass across a lifetime in the current literature is available, showing both variables 
start to decline at about the fourth decade with heterogenous changes in time and 
magnitude.23  
Muscle Strength: As illustrated by Dodds et al.24, normative data from twelve 
British studies of grip strength across the life course suggests that grip strength increases 
in youth and young adulthood with a peak reached in early adulthood (up to ~40 years of 
age).24 Strength in men and women may develop at a similar pace until adolescence.24 
This phase is followed by a more pronounced and rapid strength gain to a higher peak 
median in males compared to their female counterparts.24 The muscle strength then 
steadily declines from midlife onwards in both sexes with an annual decrease of 1.5% 
and an even more accelerated reduction of around 3% per year after the age of 60.24,25 By 
age 80, the prevalence of weak grip strength is approximately 23% in males and 27% in 
females.24  
Muscle Mass: Similarly, the decline in skeletal muscle mass starts dwindling in 
the third or fourth decade of life.19 Researchers estimate that approximately 20% of 
muscle mass can be lost by the age of 70 years.26 While men usually show higher muscle 
mass accumulations over time, they also suffer greater losses of muscle mass in later 
adulthood and old age.25 Overall, after the age of 35 years, healthy men and women can 
expect a loss in muscle mass of around 1-2% per year.27 
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Figure 1: Disproportionate decline of leg muscle strength and leg muscle mass across the 
life course. Figure adopted from Ferrucci et al.23. 
 
With advancing age, there is an obvious tendency of disassociation between 
changes in muscle strength and muscle mass (Figure 1).23 Findings of a longitudinal 
study indicate that even well-functioning older men and women revealed a 3-fold greater 
loss in muscle strength than in muscle mass over the course of 3 years of follow-up.28 
Several other studies have already confirmed the hypothesis that the decrease in muscle 
strength is much greater than the decline in muscle mass.2,23,24,29 As a consequence, 
muscle strength has been considered as the key characteristic to diagnose sarcopenia.18  
Muscle power, which is specified as the product of force and velocity of muscle 
contraction, has shown an earlier and more drastic decline with aging compared to 
muscle strength and muscle mass.29,30 In this context, muscle power has been identified 
as a better predictor of functional performance measures than other sarcopenic 
parameters among older adults.30 However, the demand of clinical settings with 
expensive tools, the necessity of a time-consuming training for clinicians and subjects, 
and the lack of standardized protocols to define low muscle power were stated as the 
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main barriers to consider this metric as an assessment instrument in sarcopenia 
research.31 Consequently, muscle power has been largely disregarded in previous muscle 
health-related investigations.31 There is a growing interest in the field of geriatrics to 
create valid muscle power measurements with better applicability in research,32,33  which 
would provide the opportunity for a standardized protocol with more reliable cut-off 
points to diagnose sarcopenia. 
1.4 Contributing Causes of Sarcopenia and the Relevance of Physical Behavior 
According to the definition imposed by EWGSOP2, the combination of low 
muscle strength and mass is used to diagnose sarcopenia in clinical practice.18 This state 
of skeletal muscle failure or insufficiency may occur due to a chronic degradation of 
muscle strength and muscle mass with time or with sudden disease/immobility.2 Skeletal 
muscle deterioration with aging is attributed to a combination of primary and secondary 
factors.2 Primary sarcopenia is specified as a progressive loss of muscle quantity and 
quality with advancing age when no other cause is evident.2 In this context, age-related 
dysfunctions of the mitochondria, the satellite cells, and the neuromuscular system are 
associated with primary sarcopenia.34 Steady decreases in hormone concentrations such 
as growth hormone, testosterone, thyroid hormone and insulin-like growth factor may 
also contribute to the reduction of muscle mass and strength during aging.35 Higher levels 
of pro-inflammatory cytokines, including tumor necrosis factor alpha and interleukin-6, 
produce catabolic signals which can diminish muscle conditions.35 Secondary aging, on 
the other hand, is influenced by lifestyle factors, environmental influences, or diseases.36 
Nutritional-, inactivity-, disease-, and iatrogenic-related health issues are stated as the 
most frequent underlying causes of secondary sarcopenia.2 The differentiation between 
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primary and secondary sarcopenia is crucial due to therapy planning.5 By knowing and 
detecting the course of these two sarcopenic manifestations, early treatment of underlying 
secondary sarcopenia can prevent additional wasting of muscle quality and quantity 
which further helps to avoid other health complications.5  
Soon after reaching the peak of muscle mass in early adulthood, the primary age-
related loss of muscle mass indicates a continuous linear decline.37 On the contrary, 
muscle wasting originated from secondary sarcopenia causes a non-linear decline with 
greater progressive decreases.37 For instance, as part of a cachexic syndrome, cancers of 
advanced stage can lead to an exponential muscle loss of up to 15% per 100 days which 
is equivalent to approximately 30 years of aging.37 Even more pronounced are the 
changes of muscle strength and mass produced by limb immobilization.38 In this regard, 
the disuse of leg muscles for the duration of 4 to 7 days can lead to a 2-6% reduction of 
muscle mass and an 8-22% decrease of muscle strength in young as well as older adults.38 
Malnutrition is also stated as an essential underlying culprit for the development of 
sarcopenia. Older adults commonly show a diminished intake of vital proteins which are 
essential for a well-functioning muscle metabolism.25 This protein-energy malnutrition 
negatively affects muscle functions.25 Study results of a four-year follow-up study 
suggest an almost four times higher risk of acquiring sarcopenia during a malnutritional 
state.39  
Low physical activity (PA) levels are also stated as a main contributor for the 
development of sarcopenia.13,40,41 Reductions in the overall number of steps per day 
(from 6,000 – 10,000 steps per day to less than 1,000 – 1,500 steps per day) can promote 
a progressive depletion of muscle strength and mass.42,43 High volumes of sedentary 
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behavior (SB), on the other hand, might accelerate the loss of muscle quality and quantity 
among older adults.44 Previous research has demonstrated that self-reported prolonged 
sitting time is associated with higher odds of sarcopenia in older adults regardless of the 
total time spent in higher PA intensity categories.45 This underscores the independent 
influence of PA and SB on sarcopenia and its parameters.44 Overall, being physically 
active across the life course has shown strong associations with better musculoskeletal 
health (Figure 2).7 
 
Figure 2: Muscle mass changes across the life course among a very active and a 
sedentary old man. Figure adopted from Valenzuela et al.7. 
 
Prior analyses have indicated that few older adults produce PA bouts longer than 
10 minutes.46,47 In this context, PA patterns change considerably with aging by displaying 
more fragmented daily patterns with shorter active bouts and longer sitting periods 
(Figure 3).48–50 These activity patterns can look very different and depend on the 
functional status of each individual.48 For instance, while a healthy older adult may 
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accumulate activity minutes in one single bout, individuals with functional limitations 
might not be able to sustain activity bouts for a long period of time which results in a 
more frequent compensatory interchange between PA and SB during a day.48 Research 
has shown that fragmented daily patterns are associated with worse physical performance 
measures,48 higher fatigability,50 cognitive impairment,51 and a greater mortality rate 
among older adults.49 As a consequence, transition states between sedentary and active 
behavior may become more important with advancing age.48–51  
 
Figure 3: Physical activity pattern change with aging. Figure provided by Jennifer A. 
Schrack, PhD. 
1.5 Statement of the Problem 
The progressively increasing demographic growth of older adults globally leads to 
major challenges for public health and medicine to prevent and combat age-related 
diseases such as sarcopenia.7 Due to the absence of effective drugs, PA seems to be the 
most promising factor to manage sarcopenia.7 Incorporating various aerobic and 
strengthening exercises have shown to provide beneficial effects on the functional ability 
in the oldest-old adult population.7 Especially PA, with a focus on resistance exercises, is 
recommended in the prevention and management of sarcopenia according to the 
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International Clinical Practice Guidelines for Sarcopenia.13 While progressive resistance 
training may enhance muscle strength and physical performance, muscle mass seems to 
be less affected by this intervention.52 The improvements in muscle strength and physical 
performance may refine activities of daily living such as walking endurance, gait speed, 
and stair climbing.53 However, fewer than 10% of older adults achieve the recommended 
amount of two strength trainings per week.54,55 Besides reported issues at the training 
facilities such as unavailability of type-, age-, and time-specific classes or poor staff 
support, worse health conditions caused by injury and illness are stated as the most 
common reasons among older adults to avoid participating in resistance training.56 
Researchers and clinicians may also consider interventions which are more easily 
adopted by older adults.53 The principle that any activity is better than no activity might 
also apply for the prevention of sarcopenia. Consequently, feasible and pragmatic daily 
PA tasks for vulnerable older adults should receive more attention in the field of 
geriatrics. Gaining a better understanding of daily PA behavior and its association with 
sarcopenia is of utmost importance to create novel and efficient interventions.  
Detailed PA patterns consisting of bouts with various frequencies, intensities, and 
durations can be captured by contemporary research-based accelerometers.49,57 Within 
this framework, the total volume of PA is specified as an amalgamated metric which 
summarizes all performed PA bouts.58 The 2nd edition of the Physical Activity 
Guidelines for Americans (PAG) released by the U.S. Department of Health and Human 
Services in 2018 suggests that people aged 65 and above should engage in a minimum of 
150 minutes of moderate to vigorous intensity physical activity (MVPA).59 
Recommended PA bouts of at least 10 minutes which were stated in previous versions of 
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PA recommendations, including the PAG 2008 and the global recommendation on PA for 
health 2010,60,61 were removed from the recently revised PAG 2018.59 This paradigm 
shift occurred based on the growing evidence that PA of any bout duration is associated 
with better health outcomes.62 However, the efficacy of the accumulated time spent in 
short PA bouts (<10 minutes) as well as long PA bouts (≥10 minutes) compared to the 
overall volume of PA is still unknown,63 especially in association with detrimental health 
outcomes such as sarcopenia.64,65  
To the best of our knowledge, only one study has yet investigated associations of 
objectively measured PA patterns compared to the overall volume of PA on defined 
sarcopenia and its indicators.66 Nevertheless, not a single study has included short PA 
bouts (<10 minutes) to this examination. The assessment of the differentiation between 
PA patterns and the total sum of PA in various intensities is highly relevant for the 
development of future health guidelines to prevent sarcopenia in the oldest-old adult 
population.  
1.6 Study Approach 
The overall goal of this study is to investigate the associations of accelerometer-
measured PA patterns and the total volume of PA with EWGSOP2 defined sarcopenia 
and its components, including muscle strength, muscle mass, and physical performance, 
among oldest-old adults. We will also complete dose-response associations of different 
patterns, volumes, and intensities of PA with sarcopenic conditions and their specified 
sarcopenia-related markers. These analyses will be realized with cross-sectional cohort 
data provided by the Health, Aging, and Body Composition (Health ABC) study which 
offers a comprehensive data collection with measurements on muscle strength, muscle 
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mass, physical performance, and accelerometry.67 A sample of 145 oldest-old adults with 
a mean age of 88.2 (2.5) years from the metropolitan areas of Memphis, TN and 
Pittsburgh, PA helps address our research aims. We hypothesize that PA patterns 
comprised of high levels of short MVPA bouts (<10 minutes) are equally important as 
the total volume of MVPA with EWGSOP2 defined sarcopenia and its parameters among 
oldest-old adults.  
This study will contribute valuable knowledge to the current literature. 
Addressing this research question will provide information on PA duration and intensity 
that can be applied in PA interventions to delay or even prevent the loss in muscle 
strength, muscle mass, and physical performance abilities and thus the onset of 
sarcopenic conditions among the oldest-old adult population. In the long term, 
understanding optimal patterns of PA for pragmatic targets for future interventions and 
public health guidelines focusing on sarcopenia and its components can improve the 
quality of life and longevity in oldest-old adults. 
1.7 Aims and Hypotheses 
Aim 1: Examine associations of accelerometer-determined physical behavior 
volume and pattern metrics with EWGSOP2 defined sarcopenia and its 
components, including muscle strength, muscle mass, and physical performance, 
among oldest-old adults. We hypothesize that higher volumes of MVPA, regardless of 
its accumulation in short MVPA bouts (<10 minutes) or in long MVPA bouts (≥10 
minutes), will demonstrate associations with lower odds of EWGSOP2 defined 
sarcopenia and better sarcopenic parameters among oldest-old adults.  
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Aim 2: Examine dose-response associations of various accelerometer-
determined physical behavior volume and pattern metrics with EWGSOP2 defined 
sarcopenia and its components, including muscle strength, muscle mass, and 
physical performance, among oldest-old adults. Physical behavior metrics will be 
grouped into tertiles. This enables us to determine health-beneficial doses for different 
patterns, volumes, and intensities of physical behavior on EWGSOP2 defined sarcopenia 
and its determinants among oldest-old adults. We hypothesize that oldest-old adults with 
the highest volumes of MVPA, whether accumulated in short MVPA bouts (<10 minutes) 
or in long MVPA bouts (≥10 minutes), will indicate favorable dose-response associations 





Since the coining of the term sarcopenia by Rosenberg in 19888 and the official 
recognition as a muscle disease in 2016 by the World Health Organization,12 a gradual 
increase of scientific interest and awareness about this public health issue has occurred. 
The purpose of this literature review is to summarize and discuss crucial findings 
regarding the association of various physical behavior metrics with defined sarcopenia 
and its related parameters, including muscle strength, muscle mass, and physical 
performance, in older adults.  
2.1 Methodological Approach for the Literature Review 
This literature search was completed by using the Covidence software which is a 
literature review manager software and a useful tool to screen research articles and 
summarize information from the existing literature. The literature review was conducted 
by implementing the following steps: (1) topic-specific literature search in an electronic 
database, (2) importing selected literature to Covidence, and (3) including or excluding 
relevant literature based on abstract- as well as full-text screening within the software. 
Research articles were collected from PubMed using the following Boolean string: 
“sarcopenia AND (physical activity OR sedentary behavior) AND (questionnaire OR 
self-report OR acceleromet* OR objectively-measur*)”. This procedure identified 391 
articles. After additionally screening the reference lists of individual research articles, 9 
supplemental studies were included in Covidence. As a result, 400 scientific papers were 
evaluated in the initial screening.  
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Research articles were included based on the following criteria: 1) observational 
studies; 2) community-dwelling population; 3) age 60 and above; 4) measurement of 
physical activity by using self-report and/or accelerometer; 5) measurement of muscle 
strength; 6) data for associations of PA with sarcopenic determinants including muscle 
strength, muscle mass, or physical performance and/or defined sarcopenia. Excluded 
were research articles with the following attributes: 1) review articles and meta-analyses; 
2) randomized controlled trials; 3) measurements of muscle mass and/or physical 
performance alone; 4) accelerometer-assessed data without any information on at least 
one of the following physical behavior metrics: total volume of PA, light intensity 
physical activity (LIPA), moderate to vigorous physical activity (MVPA), bouts of PA, 
total time spent in SB or bouts and breaks in sedentary time. Due to the limited data 
among the oldest-old adult population, we decided to collect studies with all older adults 
defined at 60+ years of age. In this abstract screening process, a total of 265 studies were 
considered as irrelevant and thus excluded from this literature review. The remaining 135 
studies were assessed for eligibility by reviewing the full text of the study. This full text 
review led to an additional exclusion of 111 studies since they provided outcomes, study 
designs, populations or settings which did not match the determined inclusion criteria. 
Overall, 24 research articles met the inclusion criteria and were selected for a 




Figure 4: Literature review summary table from Covidence regarding the associations of 
physical behavior metrics with defined sarcopenia and/or its components. 
2.2 Association of Physical Activity with Defined Sarcopenia and its Components 
among Older Adults 
2.2.1 Self-report Measurement of Physical Activity 
Overview: 16 out of 24 studies used self-report questionnaires for the assessment 
of PA. This high proportion of employing subjective methods was expected since 
measuring PA by questionnaire is known to be more cost-effective and simpler to 
administer in comparison to accelerometry.68 High costs and a lack of technical expertise 
are stated as the most common barriers for applying accelerometers in epidemiological 
research.69 Self-report measurements are still considered as a solid method for studies 
with large populations.69 In addition, questionnaires provide the ability to evaluate 
different types of PA and can be applied for a long period of time.70 
Since PA is a multidimensional construct, each instrument has its strengths and 
limitations which explains the absence of a gold-standard subjective method.71 The 
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International Physical Activity Questionnaire (IPAQ) is still the most used self-report PA 
questionnaire globally.72 This also remains true for our literature review in which one 
quarter of the studies conducted the IPAQ.  
Study Outcomes Review: As illustrated in Table 2, the association of self-report 
PA with defined sarcopenia and its components, including muscle strength, muscle mass, 
and physical performance, provided conflicting information. These inconsistent results 
may be caused by the diversity of applied self-report methods to evaluate PA and the 
various approaches to define sarcopenia. Notably, the measurement of gait speed as an 
indicator of physical performance was most frequently related with self-report PA.  
Several unique findings from the self-report PA studies were of interest. 
Structured daily schedules with frequent engagement in active hobbies across the life 
course may help to maintain better muscle health among the old-age population.73 The 
transition from work life to retirement might be a vital point in time due to critical 
alterations on the structure of daily routines.73 Outcomes from a Japanese population-
based cohort study indicated a significant relationship between exercise habits in middle 
age and sarcopenia in older age even after adjusting for age, sex, and body mass index.74 
Older adults with higher PA levels were more likely to remain in the normal muscle 
health state which was described as having muscle strength, muscle mass, and physical 
performance above the specified cut-off values for sarcopenia.75 However, according to 
longitudinal outcomes from Yu et al.76, once participants were diagnosed with 
sarcopenia, the number of returns to a non-sarcopenic condition was low. Based on this 
information, higher levels of PA may prevent older adults of becoming sarcopenic but 
may not be effective enough to help achieve a return to a non-sarcopenic state.  
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Table 2: Characteristics of observational studies looking at associations of self-report physical activity with defined sarcopenia 
and/or sarcopenia-relevant metrics 
Study Characteristics Exposure Information Outcome Information Findings 





























While current walking 
habits indicated no 
association with 
sarcopenia, individuals 
with exercise habits in 
middle age had 







60+ 1149 Brazil 





DXA Gait speed 
Other than men, women 
with low levels of PA 
were associated with a 
lower likelihood for 
sarcopenia.  









and total PA 
demonstrated no 
association with MS. 










Participants (≥ 80 years) 
with insufficient PA 
levels had higher odds for 















Higher levels of MVPA 
suggested no associations 
with MS, MM, and PP. 




60-92 836 China IPAQ, long form  AWGS 
Grip 
strength 
BIA Gait speed 
The association between 
PA levels and sarcopenia 
was not significant in the 
multivariate analysis.  




60-92 834 China IPAQ, long form  AWGS 
Grip 
strength 
BIA Gait speed 
The multivariate model 
demonstrated no link 
between PA and 
sarcopenia.  











Higher participation rates 
in aerobic and 
strengthening exercise 
were significantly 
associated with better MS 








66-93 2309 Iceland N/A EWGSOP 
Grip 
strength 
CT Gait speed 
More than 1 hour per 
week of MVPA was 
correlated with lower 







70-79 2928 USA 
Standardized 
questionnaire designed 
specifically for the 




DXA Gait speed 
Higher levels of PA 
lowered the likelihood of 




























Several PP measures were 
positively linked with 
continuous PA at 1-hour 
intervals. Higher 
continuous PA at 1-hour 
interval with a total 
volume of PA ≥ 2.5 hours 
per week was correlated 
with better walking speed 











BIA Gait speed 
Low levels of PA were 
not related with 
sarcopenia.  




60+ 2633 China 
Validated 
questionnaires used in 








Higher levels of PA were 
significantly correlated 
with better grip strength 
and better gait speed 
measures. 




65+ 844 Taiwan N/A N/A 
Grip 
strength 
DXA Gait speed 
Lower MS, MM, and PP 
measures were related 
with the joint association 
of physical inactivity and 
poor insulin sensitivity. 
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Yu et al. 
(2014)76 
Cohort 65+ 4000 China PASE EWGSOP 
Grip 
strength 
DXA Gait speed 
The risk of sarcopenia 
was lower in participants 
with higher total volumes 
of PA. Higher levels of 
PA were not correlated 
with the reversibility of a 
lower risk for sarcopenia. 








Gait speed;  
RCS 
Only gait speed as a 
metric of PP was 
positively associated with 
physical exercise. 
Abbreviations: AWGS: Asian Working Group of Sarcopenia; BIA: bioelectrical impedance analysis; CHAMPS: Community Healthy Activities Model Program for Seniors; 
CT: computerized tomography; DXA: dual-energy X-ray absorptiometry; EWGSOP: European Working Group on Sarcopenia in Older People; IPAQ: International 
Physical Activity Questionnaire; MM: muscle mass; MS: muscle strength; MVPA: moderate to vigorous physical activity; N/A: Not available; PA: physical activity; PASE: 
Physical Activity Scale for the Elderly; PP: physical performance; RCS: repeated chair stand test; SPPB: short physical performance battery; TUG: timed up and go test. 
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2.2.2 Objective Measurement of Physical Activity 
Overview: A total of 9 investigations applied objective measurements to examine 
associations of behavioral activity with defined sarcopenia and its parameters. 
Accelerometers used in PA research are small wearable devices with the main purpose of 
recording accelerations triggered by body movements. This allows the collection of 
various PA-related measures in a free-living environment.70 Accelerometry has gained 
popularity among researchers in recent decades since its usage solved several limitations 
of subjective assessments such as lack of robustness to estimate light or moderate intense 
activities or to quantify energy expenditure.71 The issue of recall bias can be reduced with 
accelerometers which alleviates the risk of human error.88 The unique capability of 
accelerometry to translate objectively measured acceleration counts via designed 
algorithms into PA intensity, volume, and duration, or metrics such as energy expenditure 
is another advantage over self-report methods.71,88  
The ActiGraph (Pensacola, FL, USA) has been the most used accelerometer by 
researchers with a utilization rate of more than 50% among published studies according 
to a systematic review.89 Based on our literature search, more than half of the collected 
studies (5 out of 9 articles) employed ActiGraphs to assess different activity behavior 
variables in older adults.  
Provided data and information from these scientific articles are summarized in 
detail below with a focus on observational findings of the association of various physical 
behavior metrics, including the total volume of PA, LIPA, MVPA, and bouts of PA, with 
defined sarcopenia as well as sarcopenia-relevant indicators including muscle strength, 
muscle mass, and physical performance.  
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2.2.2.1 Total Volume of Physical Activity 
Overview: The total volume of PA is a summarizing metric which includes the 
dimensions of frequency, intensity, and duration of activity bouts.58 Accelerometry has 
the ability to provide total activity counts which indicates an estimation of the total time 
spent in PA.58  
Study Outcomes Review: 4 out of 9 studies from our literature review 
investigated the association of the accelerometer-assessed total volume of PA with 
defined sarcopenia and its determinants (Table 3). Higher total activity counts were 
significantly related with lower odds of sarcopenia.64,90 In this context, Sanchez-Sanchez 
et al.64 demonstrated a positive correlation between total activity counts and all 
sarcopenia-relevant indicators including muscle strength, muscle mass, and physical 
performance. Westbury et al.90 also reported associations of higher accelerometer-
assessed volumes of PA with a lower likelihood of sarcopenia and better gait speed as a 
measure of physical performance. However, converse to the previous findings from 
Sanchez-Sanchez et al.64, there were no significant correlations with muscle strength and 
muscle mass. In addition, Bann et al.78 reported a link between objectively measured PA 
and grip strength in men, but not in women. This gender-specific difference may be 
explained by the types of upper limb strengthening activities in which men may partake 
more frequently than women.78 While overall levels of PA were inconsistently related 
with muscle strength and muscle mass measures, physical performance indicated a 
significant association with the total quantity of activity across all collected studies. 
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Table 3: Characteristics of observational studies looking at associations of total activity counts with defined sarcopenia and/or 
sarcopenia-relevant metrics 
Study Characteristics Exposure Information Outcome Information Findings 












Measure Main Findings 




70-89 1130 USA 
ActiGraph GT3X: 





Higher levels of PA 
were significantly 
associated with better 
grip strength in men 
but not in women.  




















Gait speed as a 
measure of PP was 
positively correlated 
with the overall 


















and its components, 
including MS, MM, 
and PP measures, 







74-84 131 UK 
GENEactiv: 
Daily time spent in 
non-sedentary PA 








Higher levels of PA 
were linked with 
better PP and a lower 
likelihood for a 
sarcopenic condition.  
Abbreviations: BIA: bioelectrical impedance analysis; DXA: dual-energy X-ray absorptiometry; EWGSOP: European Working Group on Sarcopenia in Older 
People; FNIH: Foundation for the National Institutes of Health; MM: muscle mass; MS: muscle strength; N/A: Not available; PA: physical activity; PP: physical 




2.2.2.2 Light Intensity Physical Activity 
Overview: Metabolic equivalents (METs) can estimate the energy expenditure of 
individuals during PA and is often used as an indicator of activity intensity.92 In this 
regard, 1 MET signifies the energy expenditure when sitting or lying at rest and increases 
during activities in higher intensities.92 The operational definitions of METs for each 
activity level are described in Figure 5.93 Light intensity physical activity (LIPA) is 
defined by METs of 1.5-2.9 which includes activities such as walking slowly or washing 
dishes.94 Health effects of LIPA are poorly understood since most published 
epidemiological studies use self-report methods which are less successful in capturing 
lower intensity activities.94 A meta-analysis from Ku et al.95 indicated that increased 
levels of LIPA provide additional health benefits above and beyond levels of MVPA. 
Due to commonly detected limited physical conditions in older adults, LIPA may offer an 
effective and feasible opportunity to replace SB which may avoid the onset of related 
chronic conditions. Since LIPA appears to be less fatiguing, activities in lower intensity 
categories can be integrated into the entire day with higher frequency and comfort for 
older adults.  
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Figure 5: Operational definitions of metabolic equivalents for each activity category. 
Figure adopted from Holtermann & Stamatakis.93 
 
Study Outcomes Review: In total, 4 investigative papers from our literature 
search collected LIPA data to analyze its relationship with defined sarcopenia and 
sarcopenia-relevant metrics (Table 4). The overall tendency of the study outcomes 
indicated that higher volumes of LIPA were not associated with lower odds of sarcopenia 
among older adults. While the provided data of the association between LIPA levels and 
all sarcopenic determinants were inconsistent, physical performance measures seem to be 
the most influenced parameter. In this regard, Scott et al.66 reported that an additional 
hour per week in LIPA led to a 12% higher likelihood of better timed up and go test 
performance in older adults.  
The effect of reducing SB while increasing LIPA tended to diminish the risk of 
becoming sarcopenic but lacked statistical significance.64 Significantly lower odds for 
sarcopenia appeared after reducing the time spent in LIPA while increasing the time 
spent in MVPA among older adults.64 Furthermore, a subdivision of LIPA into two 
intensity categories defined as lower-LIPA and higher-LIPA may provide supplemental 
information. For instance, Bann et al.78 characterized low-LIPA as minute-by-minute 
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acceleration counts between 100 and 1040 while higher-LIPA was identified after 
reaching between 1041 and 1951 acceleration counts per minute. In this context, an 
additional hour of higher-LIPA led to a 6 kg or a 19% higher performance in grip 
strength among men.78 In summary, these study results may conclude just minor effects 
of LIPA on muscle strength and muscle mass but a positive association with physical 
performance. As a consequence, spending more time in LIPA might not influence muscle 
strength and muscle mass but may be important for maintaining physical performance. 
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Table 4: Characteristics of observational studies looking at associations of light intensity physical activity with defined 
sarcopenia and/or sarcopenia-relevant metrics 
Study Characteristics Exposure Information Outcome Information Findings 


















70-92 1268 UK 
ActiGraph GT3X: 





MAMC  Gait speed 
Gait speed alone was 
positively related with the 
















Higher-LIPA was positively 
associated with MS in men but 















DXA Gait speed 
Only minor effects of LIPA on 
sarcopenia and its determinants 
were indicated. 




70+ 3334 Sweden 
ActiGraph GT3X+: 





Higher volumes of LIPA were 
positively associated with MM 
and PP. 
Abbreviations: DXA: dual-energy X-ray absorptiometry; EWGSOP: European Working Group on Sarcopenia in Older People; EWGSOP2: European Working Group 
on Sarcopenia in Older People 2; FNIH: Foundation for the National Institutes of Health; LIPA: light intensity physical activity; MAMC: mid-upper arm muscle 
circumference; MM: muscle mass; MS: muscle strength; N/A: Not available; PA: physical activity; PP: physical performance; SB: sedentary behavior; TUG: timed up 
and go test. 
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2.2.2.3 Moderate to Vigorous Intensity Physical Activity 
Overview: Moderate to vigorous intensity physical activity (MVPA) is the 
merged term for the combination of moderate intensity PA which is equivalent to 3-5.9 
METs and vigorous-intensity PA which corresponds to the equal or greater amount of 6 
METs.97 The 2018 Physical Activity Guidelines for Americans (PAG) suggests that 
people aged 65 and above should engage in a minimum of 150 minutes MVPA in order 
to improve overall health conditions.59 A strong consensus among epidemiological 
experts can be found regarding the positive health benefits of MVPA on reducing all-
cause mortality.98 Nevertheless, there are still many unanswered questions regarding the 
association of MVPA on underlying health conditions including sarcopenia.  
Study Outcomes Review: Based on our literature review, 6 articles examined the 
association of total MVPA volumes with defined sarcopenia and its parameters (Table 5). 
The majority of the collected studies implied significant relationship between high levels 
of MVPA and lower odds for a sarcopenic condition. Likewise, better physical 
performance measures were significantly correlated with high volumes of MVPA across 
all collected studies. While muscle strength also displayed a strong link with MVPA, 
muscle mass was inconsistently related with this metric. These findings suggest that 
MVPA in older adults may have a more potent impact on the maintenance of muscle 
strength and physical performance compared to muscle mass.  
Participants with sarcopenia spent significantly less time in MVPA compared to 
their counterparts without sarcopenia.66 Furthermore, the odds for a severe sarcopenia 
diagnosis were considerably lower among participants with higher daily volumes of 
MVPA even after adjusting for several confounding factors.96 Within this framework, 
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substituting 1 hour of SB with 1 hour of MVPA per day was significantly related to better 
sarcopenia-relevant outcomes.64 Scott et al.66 estimated lower likelihoods of 20%, 12%, 
and 66% for diminished muscle strength, muscle mass and physical performance 
following an increment of 1 hour per week in MVPA, respectively. In conclusion, MVPA 
might play a role in the prevention of sarcopenia.  
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Table 5: Characteristics of observational studies looking at associations of moderate to vigorous intensity physical activity with 
defined sarcopenia and/or sarcopenia-relevant metrics 
Study Characteristics Exposure Information Outcome Information Findings 


















70-92 1268 UK 
ActiGraph GT3X: 








MS and PP measures 
indicated a positive 
association with MVPA. 
Higher volumes of MVPA 
were also related with lower 






65-79 36 Spain 
ActiGraph GT3X:  
PA (min/day) divided 
into moderate and 





A positive relationship 
between grip strength and 







60-64 1727 UK 
Actiheart: 












Significant associations of 
higher MVPA levels with 
better MS and several PP 


















Expanding the time spent in 
MVPA by 1 hour per day 
was significantly associated 
with a lower likelihood for 
sarcopenia and better MS, 
MM, and PP. 
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Scott et al. 
(2020)66 
Cross-
sectional 70+ 3334 Sweden 
ActiGraph GT3X+: 
Total MVPA time (h) EWGSOP2 
Grip 
strength iDXA TUG 
Higher volumes of MVPA 
were significantly associated 
with probable or confirmed 
sarcopenia. All sarcopenia-
relevant parameters were 







74-84 131 UK 
GENEactiv: 
Daily time spent in 







More time spent in MVPA 
demonstrated no association 
with sarcopenia and its 
components. 
Abbreviations: BIA: bioelectrical impedance analysis; DXA: dual-energy X-ray absorptiometry; EWGSOP: European Working Group on Sarcopenia in Older People; 
EWGSOP2: European Working Group on Sarcopenia in Older People 2; FNIH: Foundation for the National Institutes of Health; MAMC: mid-upper arm muscle 
circumference; MM: muscle mass; MS: muscle strength; MVPA: moderate to vigorous physical activity; N/A: Not available; PA: physical activity; PP: physical 




2.2.2.4 Bouts of Physical Activity 
Overview: Since the publication of the Physical Activity and Health 
recommendation by the Centers for Disease Control and Prevention and the American 
College of Sports Medicine in 1995,101 MVPA bouts have been endorsed by PA 
epidemiologists over a period of more than 20 years.102 At this point in time, intermittent 
bouts of 8 to 10 minutes MVPA were considered as health beneficial as long as the total 
volume of 30 minutes MVPA on preferably each day of the week was achieved.101 The 
intention of including a PA bout suggestion was to encourage people to be more active by 
providing more flexibility regarding the accumulation of the recommended total volume 
of MVPA.101  
In 2008, the recommendations created by the Physical Activity Guideline for 
Americans (PAG) concluded that MVPA bouts should be realized for at least 10 minutes 
in order to attain substantial health benefits.60 The recommended guidance of performing 
MVPA bouts with a length of 10 minutes or longer was predominantly based on self-
report studies.102 The recently revised 2018 PAG excluded the recommended PA bouts of 
at least 10 minutes with the argument that free-living PA was mainly performed 
sporadically with a duration lower than 10 minutes.62 Findings from a systematic review 
of cross-sectional and prospective cohort studies conducted by Jakicic et al.62 indicated 
that any PA bout lower than 10 minutes was still related to better results in a variety of 
health-specific outcomes as long as the total recommended volume of PA was 
accumulated.  
However, there is still a need to investigate and understand PA patterns of 
different target groups and their association with various health outcomes. These studies 
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may be particularly important for populations who have issues performing PA bouts 
longer than 10 minutes. According to research results from Saint-Maurice et al.47, more 
than 30% of US adults older than 40 years of age produced zero PA bouts longer than 10 
minutes. This proportion is expected to increase even further in the growing old-age 
population since the duration of PA bouts tend to decrease progressively with aging.49  
In general, knowledge about the efficacy of PA bouts in comparison with the total 
volume of PA in older adults is still scarce.63 Additionally, a better understanding of the 
relationship between the influence of various MVPA bout durations and health outcomes 
would enable better tailored and more effective PA recommendations for older adults.103 
Jefferis et al.63 reported a significant association between accumulated sporadic MVPA 
bouts with periods of less than 10 minutes among older adults and a decreased risk of all-
cause mortality. Another study indicated that older adults who achieved the PA 
guidelines showed higher muscle mass and physical function measures compared to 
inactive participants regardless of the type of accumulation, whether realized in short or 
in long bouts.104  
Study Outcomes Review: Only one investigation provided information regarding 
the association of PA bouts with sarcopenia and its indicators (Table 6). Scott et al.66 
reported that the vast majority of various long MVPA bouts (≥10 minutes) was associated 
with lower odds for probable or confirmed sarcopenia and their components. Moreover, 
each LIPA bout duration from 10-19 minutes to ≥60 minutes indicated positive 
correlations with muscle mass and physical performance, but not with muscle strength.66 
Overall, these findings implied that various patterns of accumulated PA did not 
demonstrate different effects on sarcopenia and its indicators compared to the total 
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volume of PA.66 Nevertheless, to the best of our knowledge, no study has investigated the 




Table 6: Characteristics of observational studies looking at associations of physical activity bouts with defined sarcopenia 
and/or sarcopenia-relevant metrics 
Study Characteristics Exposure Information Outcome Information Findings 












Measure Main Findings 
Scott et al. 
(2020)66 
Cross-
sectional 70+ 3334 Sweden 
ActiGraph GT3X+: 
Total number of bouts 
for LIPA and MVPA 
EWGSOP2 Grip strength iDXA TUG 
The pattern in which PA was 
accumulated did not 
influence significant 
associations of the total 
volume of PA with 
sarcopenia and its 
parameters. 
Abbreviations: DXA: dual-energy X-ray absorptiometry; EWGSOP2: European Working Group on Sarcopenia in Older People 2; LIPA: light intensity physical 




2.3 Association of Sedentary Behavior with Defined Sarcopenia and its Components 
among Older Adults 
2.3.1 Self-report Measurement of Sedentary Behavior 
Overview: Independent from PA, sedentary behavior (SB) reveals a negative 
impact on human health.105 SB is defined as a waking activity which requires an energy 
expenditure of less than or equal to 1.5 METs.105 The total daily amount of sedentary 
time may reach its peak at the older age range.106 According to a systematic review 
published by Harvey et al.107, accelerometer data demonstrated that 67% of the global 
old-age population remained sedentary for more than 8.5 hours per day. These overall 
high amounts of sitting time are associated with an increased risk for all-cause mortality 
as well as with chronic illnesses such as cardiovascular disease and type 2 diabetes.108  
A total of 9 studies from our literature review were collected regarding the 
association of SB with defined sarcopenia and its indicators. Two studies applied self-
report measures and 7 assessed SB with accelerometry. Notably, one study used a 
combination of self-report and accelerometer tools to evaluate sitting behavior. Similar to 
the PA measurement, the application of self-report methods to investigate the link 
between SB and health outcomes commonly leads to considerably underestimated 
outcomes which attenuates the internal validity of the study. On the other hand, in 
comparison to device-based assessments, self-report measures may be very useful for the 
gathering of contextual information such as type of performed SB.109  
Study Outcomes Review: In sum, 2 studies applied self-report methods in order 
to evaluate the association of SB with defined sarcopenia and its determinants (Table 7). 
The cross-sectional analysis performed by Gianoudis et al.45 indicated that an increment 
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of the total sitting time by 1 hour led to a 33% higher odds for sarcopenia. Higher levels 
of TV viewing, on the other hand, were related to lower leg muscle mass.45 These study 
results imply that the impact on sarcopenic measures may vary based on the type of 
performed SB. A meta-analysis with data from more than 1 million participants showed 
that the effect of TV-viewing time was more strongly associated with all-cause mortality 
than the daily sitting time.110 Plausible reasons for this difference might be the lack of 
sedentary breaks and common dietary behaviors during TV viewing.110,111 In this context, 
TV viewing time might also have a more adverse influence on muscle strength, muscle 
mass, and physical performance than other types of SB. 
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Table 7: Characteristics of observational studies looking at associations of self-report sedentary behavior with defined 
sarcopenia and/or sarcopenia-relevant metrics  
Study Characteristics Exposure Information Outcome Information Findings 






















Total SB time was not 















Each 1-hour more of total 
sitting time per day was 
related with higher odds of 
sarcopenia. Higher TV 
viewing times were linked 
with lower leg lean mass.  
Abbreviations: CHAMPS: Community Healthy Activities Model Program for Seniors; DXA: dual-energy X-ray absorptiometry; EWGSOP: European Working 
Group on Sarcopenia in Older People; MM: muscle mass; MS: muscle strength; N/A: Not available; PP: physical performance; RCS: repeated chair stand test; SB: 




2.3.2 Objective Measurement of Sedentary Behavior 
Overview: In epidemiological research, the device-based assessment of SB is 
considered as the more valid and reliable method in a free-living environment compared 
to self-report measurements.112 The ActiGraph GT3X is a primarily energy-expenditure 
algorithm driven instrument.112 This wearable device can use a specific threshold of 
activity counts which should reflect energy expenditure levels of less than 1.5 METs in 
order to define SB.112 The activPAL, on the other hand, focuses on physical position 
measurements.112 Both devices induce bias owing to the misclassification of SB.112 For 
instance, ActiGraphs are less able to differentiate between postures since they fully focus 
on the intensity of movements.113 Thus, activities of LIPA are commonly misclassified as 
SB and vice versa because standing positions usually fall below the determined activity 
counts threshold.113 In contrast, activPALs which have set their main focus on posture are 
incapable of finding differences between SB and active sitting or lying with MET values 
of more than 1.5 such as several forms of weightlifting.112  
While energy-expenditure driven tools such as the ActiGraph may provide more 
valid outcomes of PA, the application of posture-directed devices such as the activPAL 
are more accurate in terms of assessing SB.112,114 Despite their limitations, both 
accelerometers can provide a relatively good estimation of SB volumes and patterns.113 
This enables investigators to get a better picture of behavioral patterns and thus of how 
and when sitting time is accumulated each day.108 
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2.3.2.1 Total Volume of Sedentary Behavior 
Study Outcomes Review: Overall, 7 investigations employed accelerometry to 
estimate the association of the total volume of SB with defined sarcopenia and its 
components (Table 8). In the majority of the collected studies, the significance of the 
associations of defined sarcopenia, muscle strength and muscle mass with the total 
volume of SB was lacking. However, physical performance seemed to be affected by the 
total time spent in SB since most of the studies displayed a significant relationship. These 
study results indicate the potentially positive effect of reducing SB on preserving physical 
function among older adults. 
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Table 8: Characteristics of observational studies looking at associations of total volume of sedentary behavior with defined 
sarcopenia and/or sarcopenia-relevant metrics  
Study Characteristics Exposure Information Outcome Information Findings 
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DXA Gait speed 
Each 1-hour increase of 
total SB was associated 
with higher odds of 
sarcopenia.  




70+ 3334 Sweden 
ActiGraph GT3X+: 





The total volume of SB 
was negatively 
associated with PP. 
Abbreviations: BIA: bioelectrical impedance analysis; DXA: dual-energy X-ray absorptiometry; EWGSOP: European Working Group on Sarcopenia in Older People; 
EWGSOP2: European Working Group on Sarcopenia in Older People 2; FNIH: Foundation for the National Institutes of Health; MAMC: mid-upper arm muscle 
circumference; MM: muscle mass; MS: muscle strength; N/A: Not available; PP: physical performance; RCS: repeated chair stand test; SB: sedentary behavior; TUG: 




2.3.2.2 Bouts and Breaks in Sedentary Time 
Overview: While a bout of SB is characterized as an interval of uninterrupted 
sitting time, sedentary breaks are described as the PA time of any intensity between two 
sedentary bouts.108 Independent of the total time spent in SB, specific sedentary patterns 
such as breaking up sedentary time every 20 minutes have been shown to provide 
favorable effects on postprandial glucose and insulin levels in overweight or obese 
adults.116 Overall, better metabolic health measures have been reported in participants 
who exhibited shorter sedentary bouts with a higher frequency of sitting breaks compared 
to those who produced prolonged SB with less breaks.117 Therefore, investigations in the 
growing elderly community may be even more important since daily sedentary bouts tend 
to increase in length with aging.48 
Study Outcomes Review: According to our literature search, 3 studies 
investigated the association of sedentary bouts or breaks with defined sarcopenia and its 
determinants (Table 9). Overall, sedentary breaks indicated non-significant associations 
with defined sarcopenia. The correlation between breaks in sedentary time and 
sarcopenia-related parameters was analyzed in 2 investigations. Only physical 
performance was positively linked with sedentary breaks based on the cross-sectional 
analysis from Aggio et al.96. However, Reid et al.115 concluded a lack of significance 
regarding this relationship. In addition, another study examined the correlation of sitting 
bouts with sarcopenic indicators. Scott et al.66 pointed out that each sedentary period 
which lasted longer than 20 minutes was related with worse outcomes of physical 
performance. Muscle strength as well as muscle mass, on the contrary, were not 
associated with any reported sedentary bout.  
46 
Table 9: Characteristics of observational studies looking at associations of sedentary bouts and breaks with defined sarcopenia 
and/or sarcopenia-relevant metrics 
Study Characteristics Exposure Information Outcome Information Findings 


















70-92 1268 UK 
ActiGraph GT3X: 
Breaks in sedentary 




MAMC Gait speed 
Sedentary breaks were 
positively related with PP. 




















Breaks of SB implied no 
correlations with all 
sarcopenia-relevant parameters 
after adjusting for various 
confounding factors. 




70+ 3334 Sweden 
ActiGraph GT3X+: 






Only TUG time as a measure 
of PP was positively related 
with sedentary bouts. 
Abbreviations: DXA: dual-energy X-ray absorptiometry; EWGSOP: European Working Group on Sarcopenia in Older People; EWGSOP2: European Working Group 
on Sarcopenia in Older People 2; FNIH: Foundation for the National Institutes of Health; MAMC: mid-upper arm muscle circumference; MM: muscle mass; MS: muscle 
strength; PP: physical performance; RCS: repeated chair stand test; SB: sedentary behavior; TUG: timed up and go test. 
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2.3.2.3 Activity Fragmentation 
Overview: Epidemiological research shows that the activity profile changes 
substantially with aging by displaying shorter PA bouts118 and longer bouts of SB.119 
Older adults often have difficulty sustaining PA for an extended period of time.48–50 This 
may lead to a frequent compensatory interchange of PA and SB during a day.48 Frequent 
transition states between a minute-by-minute captured sedentary and active behavior via 
accelerometry indicate a higher PA fragmentation which have been previously shown to 
be associated with worse health status in older adults.48–51 
To the best of our knowledge, only one study has looked at the associations of 
activity fragmentation with sarcopenia and its indicators.45 However, physical behavior 
metrics were assessed via self-report in this study which may have diminished the 
validity of the calculated activity fragmentation.45 An investigative approach of applying 
accelerometry to identify the association of activity fragmentation with sarcopenia status 
and its parameters is missing. Activity fragmentation can be estimated with the active-to-
sedentary transition probability (ASTP) index which is calculated by dividing the number 
of PA bouts with the sum of minutes spent in PA (Figure 5).48 Utilizing the active-to-
sedentary transition probability (ASTP) index in epidemiological studies might enable 
researchers to obtain a more profound understanding of fragmented activity patterns 




Figure 6: Calculation of the activity-to-sedentary transition probability. Figure provided 
by Jennifer A. Schrack, PhD. 
2.4. Strengths and Limitations of Applying Subjective- and Objective Measurement 
Methods in Studies with Older Adults 
As previously indicated, selecting the appropriate measurement tool to evaluate 
PA or SB in a free-living environment is an important component of the research 
methodology with pivotal consequences on the validity and reliability of the study 
outcomes. Prior to choosing a suitable measure of PA or SB, imperative attributes such as 
the evidence-based quality of each methodological approach and the benefit-cost analysis 
should be considered.71 Study characteristics, population characteristics, instrument 
characteristics, and activity characteristics are factors to contemplate when selecting the 
best possible method of activity evaluation.88 The most commonly used approach to 
assess PA in epidemiological research is still the self-report questionnaire.120 
Questionnaires are described as valuable and cost-effective instruments to measure 
various types of PA, whether these activities are performed statically, such as 
weightlifting, or dynamically, such as walking.70 In addition, owing to their simple 
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operationality for responder and respondent, subjective measures are advantageous in 
studies with large sample sizes as well as long time periods.70  
However, PA is highly complex and consists of a broad activity spectrum 
regarding the volume and intensity.58 This multicomponent shape of PA leads 
involuntarily to an incidental recall bias and thus to an over- or underestimation of the 
test results which is caused by the inability of self-report questionnaires to obtain precise 
minute-by-minute measures.121 Similar to that, SB measures assessed via subjective 
methods also commonly experience underestimation of the true study outcomes.122  
Accelerometry, on the other hand, can translate body acceleration counts into 
measures of energy expenditure.70 The correct utilization of accelerometers enables 
investigators to collect more accurate information on the volume and frequency of 
various intensities.70 However, activities such as different forms of strength training or 
cycling are often not accurately detected by accelerometry.70  
Strengths and limitations of PA measurement methodologies also vary between 
the differences of population attributes, including age, gender, body weight, or co-morbid 
conditions, which lead to even more pronounced difficulties of selecting an effective and 
accurate assessment method.71 For instance, activity patterns experience substantial 
changes across the life course with overall steady decreases of PA levels from young to 
old.118 Due to commonly diminished physical functions or multimorbid conditions, older 
adults show large dissimilarities regarding the type and intensity of PA compared to the 
younger population.123 In this regard, older adults usually exhibit high levels of LIPA 
such as casual walking or different types of household tasks which may be difficult to 
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capture via self-report questionnaires owing to their incorrect conceptualization of this 
intensity range.124  
Additionally, most of the self-report assessments substantially underestimate the 
actual levels of SB and frequently record only about a half of the accelerometer 
measurements among older adults.125 The application of accelerometry in old-age 
population studies helped alleviating parts of the issues by being able to collect low 
activity levels and by limiting recall bias.124  
However, the variety of accelerometer types and the different data collection and 
processing criteria provides challenges for researchers to select the best possible device 
for measuring PA and SB. Age-specific data collection protocols such as device 
placement or sampling frequency as well as data processing criteria such as filters, epoch 
length, non-wear time definition, cut-points, and algorithms are imperative settings which 
need to be carefully considered.89 In this regard, the misclassification of behavioral 
activities in which most accelerometers exhibit limited functional abilities to differentiate 
between SB and LIPA is considered as a huge limitation of objective measurements.112 
For instance, while the activPAL as a posture-focused device may ignore active sitting 
such as weightlifting, the ActiGraph as an energy expenditure-prone wearable may 
disregard passive standing.112,126  
2.5 Literature Review Summary 
The broad spectrum of activity behavior in terms of length, intensity, and 
frequency seems to influence sarcopenia and its components including muscle strength, 
muscle mass, and physical performance. Our systematic literature review implied positive 
associations of LIPA with physical performance. In this context, LIPA might become 
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more important with advancing age since low intensities can be endured for a longer 
period of time and are easier to perform with higher frequencies during a day. Higher 
volumes of LIPA also lead to a considerable reduction of SB and its potentially 
associated negative consequences on muscle health.  
MVPA seems to be the most effective type of intensity to reduce the odds of 
sarcopenia according to our systematic literature search. Implementing higher levels of 
MVPA in daily routines may be essential for lowering the risk of a sarcopenia diagnosis. 
However, as previously discussed, MVPA may be difficult to sustain for long time 
periods by older adults. Accumulated activity bouts with time periods of less than 10 
minutes seem to be understudied despite their common presence throughout day-to-day 
activity patterns among the old-age population. To the best of our knowledge, no study 
has investigated the association of short sporadic activity bouts (<10 minutes) with 
defined sarcopenia and its individual components. Identifying this relationship via 
observational studies may fill a valuable gap in geriatric research.  
In contrast to the mainly positive effects of PA, SB shows rather adverse 
implications on sarcopenia-related physical performance measures. Long sedentary bouts 
and short sitting breaks presented an inverse relationship with physical performance 
among older adults. Notably, insufficient information was available regarding the 
association of activity fragmentation with sarcopenia and its parameters. The activity 
fragmentation might indicate a useful marker for deteriorated muscle health among older 
adults. 
Across the study outcomes of our literature review, higher volumes of PA and 
lower volumes of SB were associated with better physical performance regardless of the 
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provided bout length and intensity. Engaging in activities with higher intensity might 
play a role to obtain an additional positive effect on muscle strength and mass and thus 
lower the odds for sarcopenia. Short MVPA bouts (<10 minutes), which might be better 
achievable for older adults, may provide enough stimuli to the muscles in order to lower 
the odds of sarcopenia and to improve sarcopenia-relevant parameters. In summary, 
investigating the relationship between the whole spectrum of activity behavior and 
sarcopenia among older adults provides huge opportunities to address this growing 






This secondary analysis will evaluate associations of accelerometer-measured PA 
patterns and total volume of PA with EWGSOP2 defined sarcopenia and its indicators, 
including muscle strength, muscle mass, and physical performance, among oldest-old 
adults. Cross-sectional cohort data from the Health, Aging, and Body Composition 
(Health ABC) study helps address this research question. The Health ABC study is an 
observational investigation with the main purpose of collecting information on a 
multitude of risk factors, encompassing weight-related health conditions and behavioral 
determinants which may lead to functional decline and loss of independence among 
healthy community-dwelling older adults. Their valuable data collection of measurements 
on body composition, strength and function as well as accelerometer-assessed PA in a 
sample of oldest-old adults contributes to the realization of our defined investigative 
aims.67 
3.2 Participants 
A study cohort composed of 3075 community-dwelling black and white men and 
women aged 70-79 years at baseline were randomly recruited from the metropolitan areas 
of Memphis, TN and Pittsburgh, PA. Participants were excluded from the study if they 
demonstrated: 1.) difficulties to walk one quarter of a mile or to climb 10 steps without 
resting; 2.) difficulties with instrumental activities of daily living; 3.) a history of cancer 
treatment in the last 3 years; 4.) a plan to move out of the geographic study area in the 
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next 3 years. Baseline data of clinical assessments as well as home interviews were 
gathered between April 1997 and June 1998. All recruited participants were followed for 
a total of 16 years with various subjective and objective evaluations each year. Written 
informed consent was given from each involving study subject. Furthermore, the 
institutional review boards from the University of Tennessee and the University of 
Pittsburgh approved the investigation.  
Cross-sectional data from year 16 was used for this analysis due to the availability 
of measures of muscle strength, body composition, physical performance, and 
accelerometry. The primary sample was analyzed for associations of various behavior 
metrics, including total activity counts, total moderate to vigorous physical activity 
(MVPA) time, total light intensity physical activity (LIPA) time, total sedentary behavior 
(SB) time, total short MVPA bouts (<10 minutes) duration, total long MVPA bouts (≥10 
minutes) duration, total number of sedentary breaks, and the active-to-sedentary 
transition probability (ASTP), with handgrip strength only, which is stated as the main 
indicator of sarcopenia and allows the definition of a probable sarcopenic state according 
to the EWGSOP2.18 One-hundred forty-seven participants from the Memphis, TN and 
Pittsburgh, PA region were included in the primary sample which was based on the 
availability of handgrip strength data tested on both hands and valid accelerometer 
measures recorded for at least 4 days.127  
As reported by EWGSOP2, confirmed sarcopenia is specified as a combination of 
low handgrip strength and low appendicular lean mass. An additional detection of low 
gait speed measures concludes a severe sarcopenic condition.18 Consequently, a 
subsample of the primary samples was created which required valid data of handgrip 
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strength, appendicular lean mass, gait speed, and accelerometry. A total of 87 participants 
located in the Memphis area were available for the subsample analysis. The subsample 
was used to examine the relationships of various physical behavior metrics with probable, 
confirmed, and severe sarcopenia and their individual components including handgrip 
strength, appendicular lean mass, and gait speed.  
3.3 Study Protocol 
3.3.1 Sarcopenia-Related Metrics 
3.3.1.1 Muscle Strength 
Upper limb muscle strength was measured with the help of an isometric hand-held 
dynamometer (Jaymar, JLW Instruments, Chicago, IL) for handgrip strength. The test 
was conducted two times for each hand with the mean of all four evaluations used for the 
analysis. Participants who reported severe hand pain or recent surgery were excluded 
from the study.  
3.3.1.2 Muscle Mass 
Total fat mass and appendicular lean mass were evaluated using whole body DXA 
(Hologic QDR 4500, software version 8.21, Bedford, MA) scans which were solely 
performed in Memphis and included as part of the subsample examination. The 
appendicular lean mass was quantified by summarizing the lean mass in arms and legs.  
3.3.1.3 Physical Performance 
Gait speed was applied as a measurement of physical performance among the 
sample of oldest-old adults. In this regard, a 20-meter course marked by an orange cone 
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at the end of the track was created. Participants were instructed to walk along the course 
with their usual pace from a specified starting point to the orange cone. The timer was 
started when the participant crossed the starting line and was stopped following the first 
step after the finish line. Moreover, the usage of walking aids, such as a cane or walkers, 
were allowed during the evaluation process.  
3.3.2 Physical Activity Assessment 
3.3.2.1 Accelerometry 
Participants were instructed to wear an ActiGraph GT3X+ accelerometer 
(ActiGraph, Pensacola, Florida, USA) on their right hip for 7 consecutive days. The 
monitors were worn during all waking hours except water-related activities such as 
swimming and taking a bath or a shower. In addition, participants were instructed to take 
off the device prior to sleep time and put it back on after getting up in the morning. 
Three-axis acceleration data in free-living conditions were captured by applying 1 second 
epoch periods. The analog acceleration signals were digitized by a 12-bit Analog to 
Digital Converter with the sampling frequency of 80 Hertz and passed through a digital 
filter that band limits the accelerometer to the frequency range of 0.25 to 2.5 Hertz in 
order to efficiently detect human motions. Afterwards, movement data from all eligible 
participants were uploaded to the ActiLife software (Version 6.5.1; ActiGraph, 
Pensacola, FL, USA) to manage and analyze the collected information.  
3.3.3 Covariates 
Demographic factors, including age, gender, race, and education level, were 
identified with an interviewer-administered questionnaire at study baseline. Body mass 
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index (BMI) data was calculated by taking the body weight (kg) and dividing by the 
height (meters) squared. A calibrated standard balance beam scale and a Harpenden 
stadiometer (Holtain Ltd, Crosswell, UK) were applied to measure the weight and height, 
respectively. Smoking status was the only measure determined at year 1 and was included 
as a covariate in our study since a previous meta-analysis has shown that cigarette 
smoking might contribute to the development of sarcopenia.128 Accelerometer wear time 
was quantified as described in Chapter 3.3.2.1. Furthermore, the prevalence of physician-
diagnosed chronic conditions, including diabetes, hypertension, history of cardiovascular 
disease, and history of cancer, were also included as potential confounders to the 
analysis. These data were ascertained by algorithms based on self-reports and medication 
use.  
3.4 Data Analysis 
3.4.1 Primary Outcome 
Sarcopenia was our primary outcome of interest. Sarcopenic indicators included 
muscle strength, muscle mass, and physical performance measures.2 Cut points for 
sarcopenia-associated parameters were provided by the revised definition of the European 
Working Group on Sarcopenia in Older People 2 (EWGSOP2)18. Probable, confirmed, or 
severe sarcopenia were defined using low upper limb muscle strength evaluated by a 
calibrated handgrip dynamometer (handgrip strength: <27 kg for men and <16 kg for 
women), low muscle mass tested by a Dual-energy X-ray absorptiometry (appendicular 
lean mass: <20 kg for men and <15 kg for women), and low physical performance 
assessed by a 20-m usual walking speed test (gait speed: ≤0.8 m/s).18 We examined each 
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sarcopenic condition as a dichotomous variable and each sarcopenia-related metric as a 
continuous variable.  
3.4.2 Primary Exposures 
3.4.2.1 Physical Behavior Volume Metrics 
The total volume of various physical behavior metrics including sedentary 
behavior (SB), light intensity physical activity (LIPA), and moderate to vigorous 
intensity physical activity (MVPA) were determined using the ActiGraph GT3X+ 
accelerometer data. We identified the total minutes of PA per day (at any bout length) of 
total activity counts, LIPA, MVPA, and SB. The classification of the overall time spent in 
different physical behavior intensities was determined using counts per minute (cpm) 
intensity threshold values. In this context, SB was categorized as <100 cpm,129 LIPA was 
categorized as 100-1040 cpm,130 and MVPA was categorized as ≥1041 cpm.130 
Participants were excluded from the study when they did not provide ≥4 days of valid 
accelerometer data of 10 hours per day.127 
3.4.2.2 Physical Behavior Pattern Metrics 
We examined MVPA split into bouts lasting <10 minutes and ≥10 minutes. This 
enabled us to compare the efficacy of short MVPA bouts (<10 minutes) and long MVPA 
bouts (≥10 minutes) with the total volume of MVPA on EWGSOP2 defined sarcopenia 
and its components. The selected duration of these 10 minute intensity bouts was based 
on the PA recommendations imposed by the PAG 2008 and the World Health 
Organization.60,61 Furthermore, although bouts were removed in the most recent 2018 
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PAG,59 there is a need for future research to understand how the accumulation of PA 
influences health outcomes.62 
We investigated the associations of the total number of sedentary breaks and 
activity fragmentation with sarcopenic status and its components. A sedentary break was 
registered when participants provided ≥100 cpm for at least 1 minute following a 
sedentary bout. The activity fragmentation was quantified with the active-to-sedentary 
transition probability (ASTP) index. This index gave us an estimation of the 
fragmentation level of the provided PA patterns. ASTP was computed for each day and 
averaged across valid days to derive a single measure for each participant.48 To calculate 
activity fragmentation in Health ABC, we used the number of breaks in SB divided by 
the total sum of minutes spent in PA. Higher activity fragmentation represents more 
interruptions in activity. 
3.5 Statistical Analyses 
Participant characteristics comprised of baseline demographic data (age, gender, 
race, and education level) and at the year 16 visit accelerometer measures of physical 
behavior metrics as well as year 16 visit sarcopenia-related metrics were summarized and 
expressed as mean (standard deviation) or median (interquartile range) for continuous 
variables or as frequency and percentage for categorical variables. Differences of 
participant baseline characteristics by sarcopenic status were determined by independent 
samples t-tests or Mann-Whitney U tests for continuous variables and chi-square tests for 
categorical variables.  
For each analysis described below we used the following variables as primary 
exposures: total activity counts, total MVPA time (min/day), total LIPA time (min/day), 
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total SB time (min/day), total MVPA minutes in short bouts (<10 minutes in duration; 
min/day), total MVPA minutes in long bouts (≥10 minutes in duration; min/day), total 
number of sedentary breaks (number of breaks/day), and ASTP (number of sedentary 
breaks / total PA time). 
Multivariate linear regression models were employed to determine the cross-
sectional association of each PA variable with sarcopenia-relevant indicators as 
continuous variables including handgrip strength, appendicular lean mass, and gait speed. 
In order to evaluate the odds for EWGSOP2 defined probable, confirmed, and severe 
sarcopenia diagnosis, binomial logistic regression models were used. This provided 
clinical relevance since we were able to understand whether sarcopenia as our primary 
outcome is associated with distinct PA behaviors and patterns. The odds of probable, 
confirmed, and severe sarcopenia were estimated for incrementally higher levels of total 
activity counts, total MVPA time (per 5 min/day), total LIPA time (per 60 min/day), total 
SB time (per 60 min/day), total MVPA <10 minute bout duration (per 5 min/day), total 
MVPA ≥10 minutes bout duration (per 5 min/day), total number of sedentary breaks (per 
1 number of sedentary breaks/day), and ASTP (per 0.1 ASTP). 
These linear and logistic regression models were adjusted for age, gender, race, 
education, and accelerometer wear time in model 1. In model 2, we adjusted for the 
covariates presented in model 1 plus lifestyle factors including BMI and smoking status. 
Model 3 provided adjustments for all covariates presented in model 2 plus chronic health 
conditions including diabetes, hypertension, history of cardiovascular disease, and history 
of cancer.  
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We also examined the dose-response associations of the total volume of PA and 
PA patterns on EWGSOP2 defined probable sarcopenia, confirmed sarcopenia, and 
severe sarcopenia among this oldest-old adult population sample. This provided crucial 
information on the linearity or non-linearity of the relationships and whether threshold 
levels exist for activity behaviors in association with sarcopenia status. Dose-response 
associations of behavioral activity metrics, including total activity counts, total MVPA 
time (min/day), total LIPA time (min/day), total SB time (min/day), total MVPA <10 
minute bout duration (min/day), total MVPA ≥10 minute bout duration (min/day), total 
number of sedentary breaks (number of breaks/day), and ASTP (number of sedentary 
breaks / total PA time), with EWGSOP2 defined probable sarcopenia, confirmed 
sarcopenia, and severe sarcopenia were evaluated. Categorical variables were created for 
each PA metric by dividing them into tertiles or groups. Participants were allocated in 
three equally sized tertiles based on their level of total activity counts, total LIPA time, 
total SB time, total MVPA <10 bout duration, total number of sedentary breaks, and 
ASTP. The first (lowest) tertile was considered the reference group. For the total volume 
of MVPA, three groups were generated in which 0-5 minutes represented the first group, 
5-10 minutes the second group, and ≥10 minute the third group in order to draw a clearer 
picture of the statistical results. Due to the expected low presence of the overall minutes 
spent in any long MVPA bouts (≥10 minute) among oldest-old adults, participants were 
either administered to the group which provided not a single long MVPA bout period or 
to the group with at least some amount of long MVPA bout duration.  
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A two-tailed hypothesis testing with an alpha level of 0.05 proved statistical 
significance of these examinations. All data were analyzed and illustrated using the 





4.1 Primary Sample 
4.1.1 Participant Characteristics 
The primary sample included 145 participants with valid handgrip strength and at 
least 4 days of 10 hours per day of accelerometer wear. One participant was excluded due 
to irregularly high acceleration counts, likely caused by accelerometer malfunction. Table 
10 presents characteristics of the final 145 participants. Fifty-two (35.9%) individuals 
were categorized as probable sarcopenic based on the applied EWGSOP2 criteria. The 
mean age was 88.2 (2.5) years and 81 (55.9%) were women, 45 (31.0%) were black race, 
and 92 (63.4%) individuals completed a postsecondary degree. Participants spent on 
average 9.6 (10.4) minutes per day or 1.1% (1.2%) of the accelerometer wear time in 
MVPA, 151.3 (58.7) minutes per day or 18.0% (7.1%) in LIPA, and 686.6 (128.0) 
minutes per day or 80.8% (7.8%) in SB. The mean handgrip strength of men was 28.2 
(6.3) kg and for women 18.0 (5.1) kg. Significant differences in handgrip strength 
between the nonsarcopenic group (men: 32.5 (4.6) kg; women: 20.5 (3.6) kg) and 
probable sarcopenic group (men: 22.8 (3.4); women: 12.2 (3.2) kg) were identified. In 
addition, significant differences were found among the data of education level, race, total 
time spent in MVPA, total time spent in MVPA bouts of <10 minutes, and total time 
spent in MVPA bouts of ≥10 minutes. However, no differences between groups regarding 
the average minutes of accelerometer wear time, total activity counts, LIPA, SB, number 
of sedentary breaks, and ASTP were discovered.
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Table 10: Participant characteristics of the primary sample 
  
Total sample 
(n = 145) 
Nonsarcopenic 
(n = 93) 
Probable sarcopenic 
(n = 52) p-value for difference 
Demographic factors     
Age, years, mean (SD) 88.2 (2.5) 88.2 (2.7) 88.3 (2.3) 0.75 
Women, n (%) 81 (55.9%) 57 (61.3%) 24 (46.2%) 0.11 
Race, n (%), black 45 (31.0%) 35 (37.6%) 10 (19.2%) 0.03 
Education, n (%), postsecondary 92 (63.4%) 57 (61.3%) 35 (67.3%) <0.01 
Site, n (%), Memphis 103 (71.0%) 67 (72.0%) 36 (69.2%) 0.87 
      
Lifestyle factors     
BMI (kg/m2), mean (SD) 27.1 (4.6) 27.52 (4.7) 26.2 (4.5) 0.10 
Current smoker, n (%) 4 (2.8%) 2 (2.2%) 2 (3.8%) 0.95 
      
Chronic health conditions     
Diabetes, n (%) 40 (27.6%) 26 (28.0%) 14 (26.9%) 1.00 
Hypertension, n (%) 109 (75.2%) 70 (75.3%) 39 (75.0%) 1.00 
History of cardiovascular disease, n (%) 50 (34.5 %) 33 (35.5%) 17 (32.7%) 0.88 
History of cancer, n (%) 42 (29.0%) 29 (31.2%) 13 (25.0%) 0.55 
      
Muscle strength     
Handgrip strength (kg), mean (SD) 22.5 (7.6) 25.1 (7.1) 17.9 (6.3) <0.01 
Handgrip strength men (kg), mean (SD) 28.2 (6.3) 32.5 (4.6) 22.8 (3.4) <0.01 
Handgrip strength women (kg), mean (SD) 18.0 (5.1) 20.5 (3.6) 12.2 (3.2) <0.01 
      
Accelerometer     
Average minutes of weartime (min/day), mean (SD) 847.6 (119.8) 837.5 (107.7) 865.6 (138.0) 0.21 
TAC (counts/day), mean (SD) 244,233 (104,544) 248,011 (107,972) 237,475 (98,779) 0.55 
% time MVPA, median (IQR) 0.7 (0.3, 1.6) 0.9 (0.4, 1.9) 0.5 (0.3, 1.0) <0.01 
% time MVPA, mean (SD) 1.1 (1.2) 1.3 (1.3) 0.8 (1.0) <0.01 
% LIPA, mean (SD) 18.0 (7.1) 18.7 (7.1) 16.9 (6.8) 0.14 
% SB, mean (SD) 80.8 (7.8) 80.0 (7.9) 82.4 (7.3) 0.08 
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MVPA (min/day), median (IQR) 5.7 (3.2, 13.2) 6.5 (3.3, 15.7) 3.9 (2.3, 8.0) <0.01 
MVPA (min/day), mean (SD) 9.6 (10.4) 11.1 (11.0) 6.9 (8.6) <0.01 
LIPA (min/day), mean (SD) 151.3 (58.7) 154.8 (57.3) 145.2 (61.3) 0.36 
SB (min/day), mean (SD) 686.6 (128.0) 671.6 (121.7) 713.5 (135.6) 0.07 
MVPA in bouts <10 min (min/day), median (IQR) 5.4 (3.2, 10.9) 6.4 (3.3, 13.8) 3.9 (2.3, 8.0) <0.01 
MVPA in bouts <10 min (min/day), mean (SD) 8.5 (8.8) 9.6 (8.9) 6.6 (8.3) <0.01 
MVPA in bouts ≥10 min (min/day), median (IQR) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) <0.01 
MVPA in bouts ≥10 min (min/day), mean (SD) 1.1 (3.2) 1.5 (3.8) 0.3 (1.5) <0.01 
Number of sedentary breaks (No. of breaks/day), 
mean (SD) 69.5 (18.9) 69.5 (15.6) 69.4 (23.8) 0.99 
ASTP, mean (SD) 0.47 (0.11) 0.46 (0.12) 0.49 (0.10) 0.12 
Notes: Bold values are significant. All data are mean +/- SD (independent samples t tests), except median (interquartile range) (Mann-Whitney U tests) and 
proportions (chi-square test). The active-to-sedentary transition probability index is calculated by dividing the total number of breaks in sedentary behavior 
with the sum of minutes spent in physical activity. 
Abbreviations: ASTP: active-to-sedentary transition probability; BMI: body mass index; LIPA: light intensity physical activity; MVPA: moderate to vigorous 
physical activity; SB: sedentary behavior; TAC: Total activity counts. 
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4.1.2 Associations of Physical Behavior Metrics with Probable Sarcopenia (Binomial 
Logistic Regressions) 
Volumes: Table 11 presents the odds ratios for the associations of physical 
behavior volume metrics with probable sarcopenia determined by EWGSOP2. After 
adjusting for age, gender, race, education, and accelerometer wear time (model 1), each 5 
minute higher per day of MVPA was related with a 28% (95% CI 0.57 to 0.92) lower 
likelihood for probable sarcopenia. This association remained significant following 
further adjustments for lifestyle factors including BMI and smoking status (OR=0.73, 
95% CI 0.58 to 0.92, model 2) as well as chronic health conditions such as diabetes, 
hypertension, cardiovascular disease, and cancer (OR=0.73, 95% CI 0.57 to 0.92, model 
3). There were no significant associations of total activity counts, LIPA, and SB with 
probable sarcopenia.   
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Table 11: Odds ratios for the associations of physical behavior volume metrics with 
probable sarcopenia 
  Dichotomous (yes/no) 
  
Probable sarcopenic  
OR (95% CI) 
Physical behavior volumes   
TAC (per 1 SD (104,544 counts))   
Model 1 0.79 (0.54 to 1.18) 
Model 2 0.78 (0.52 to 1.16) 
Model 3 0.77 (0.51 to 1.15) 
Total MVPA (per 5 minutes higher)   
Model 1 0.72 (0.57 to 0.92) 
Model 2 0.73 (0.58 to 0.92) 
Model 3 0.73 (0.57 to 0.92) 
Total LIPA (per 60 minutes higher)   
Model 1 0.81 (0.55 to 1.19) 
Model 2 0.83 (0.56 to 1.22) 
Model 3 0.82 (0.55 to 1.21) 
Total SB (per 60 minutes higher)   
Model 1 1.30 (0.91 to 1.84) 
Model 2 1.27 (0.89 to 1.81) 
Model 3 1.28 (0.89 to 1.84) 
Notes: Bold values are significant. Probable sarcopenia is defined using low upper limb muscle 
strength evaluated by a calibrated handgrip dynamometer (grip strength: <27 kg for men and <16 kg 
for women). 
Abbreviations: LIPA: light intensity physical activity; MVPA: moderate to vigorous physical activity; 
OR (95% CI): odds ratio (95% confidence interval); SB: sedentary behavior; TAC: Total activity 
counts. 
Model 1: adjusted for age, gender, race, education, accelerometer wear time 
Model 2: model 1 + lifestyle factors (BMI, smoking status) 
Model 3: model 2 + chronic health conditions (diabetes, hypertension, history of cardiovascular 
disease, history of cancer) 
 
Patterns: Regarding the associations of physical behavior pattern metrics with 
probable sarcopenia in Table 12, we found that 5 minutes per day higher levels of short 
MVPA bouts (<10 minutes) were associated with 27% (95% CI 0.56 to 0.96) lower odds 
for a probable sarcopenia diagnosis in the final adjusted model. For longer MVPA bouts 
(≥10 minutes), each 5 minute more per day demonstrated a 69% (95% CI 0.10 to 0.95) 
lower likelihood for probable sarcopenia after final adjustment. Sedentary breaks and 
ASTP were not associated with probable sarcopenia. 
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Table 12: Odds ratios for the associations of physical behavior pattern metrics with 
probable sarcopenia 
  Dichotomous (yes/no) 
  
Probable sarcopenic  
OR (95% CI) 
Physical behavior patterns   
MVPA <10 minute bouts (per 5 minutes higher)   
Model 1 0.73 (0.56 to 0.95) 
Model 2 0.74 (0.57 to 0.96) 
Model 3 0.73 (0.56 to 0.96) 
MVPA ≥10 minute bouts (per 5 minutes higher)   
Model 1 0.30 (0.10 to 0.91) 
Model 2 0.30 (0.10 to 0.94) 
Model 3 0.31 (0.10 to 0.95) 
Number of sedentary breaks (No. of breaks/day)   
Model 1 1.00 (0.98 to 1.02) 
Model 2 1.00 (0.98 to 1.02) 
Model 3 1.00 (0.98 to 1.02) 
ASTP (per 0.1 ASTP)   
Model 1 1.29 (0.94 to 1.79) 
Model 2 1.26 (0.91 to 1.74) 
Model 3 1.25 (0.90 to 1.73) 
Notes: Bold values are significant. Probable sarcopenia is defined using low upper limb muscle 
strength evaluated by a calibrated handgrip dynamometer (grip strength: <27 kg for men and <16 kg 
for women). The active-to-sedentary transition probability index is calculated by dividing the total 
number of breaks in sedentary behavior with the sum of minutes spent in physical activity. 
Abbreviations: ASTP: active-to-sedentary transition probability; MVPA: moderate to vigorous 
physical activity; OR (95% CI): odds ratio (95% confidence interval). 
Model 1: adjusted for age, gender, race, education, accelerometer wear time 
Model 2: model 1 + lifestyle factors (BMI, smoking status) 
Model 3: model 2 + chronic health conditions (diabetes, hypertension, history of cardiovascular 
disease, history of cancer) 
4.1.3 Associations of Physical Behavior Metrics with Handgrip Strength 
(Multivariate Linear Regressions by Gender) 
Applying multivariate linear regressions by gender among the primary sample (Table 13 
and Table 14) provided no statistically significant association of any physical behavior 
volume or pattern variable with handgrip strength.   
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Table 13: Linear regression associations of physical behavior volume metrics with 
handgrip strength by gender 
  
Handgrip strength (kg)  
ß (95% CI) 
  Men (n = 64) Women (n = 81) 
Physical behavior volumes     
TAC (per 1 SD (104,544 counts))     
Model 1 0.69 (-0.84 to 2.22) 0.59 (-0.63 to 1.82) 
Model 2 0.91 (-0.67 to 2.49) 0.62 (-0.62 to 1.86) 
Model 3 0.71 (-0.86 to 2.27) 0.41 (-0.91 to 1.72) 
Total MVPA (per 5 minutes higher)     
Model 1 0.53 (-0.09 to 1.14) 0.63 (-0.04 to 1.30) 
Model 2 0.58 (-0.04 to 1.20) 0.58 (-0.10 to 1.28) 
Model 3 0.45 (-0.16 to 1.07) 0.57 (-0.13 to 1.28) 
Total LIPA (per 60 minutes higher)     
Model 1 0.04 (-1.50 to 1.58) 0.98 (-0.24 to 2.20) 
Model 2 0.13 (-1.43 to 1.69) 0.93 (-0.33 to 2.18) 
Model 3 0.18 (-1.39 to 1.74) 0.70 (-0.66 to 2.06) 
Total SB (per 60 minutes higher)     
Model 1 -0.24 (-1.62 to 1.13) -0.95 (-2.06 to 0.15) 
Model 2 -0.34 (-1.73 to 1.06) -0.90 (-2.04 to 0.24) 
Model 3 -0.33 (-1.72 to 1.07) -0.72 (-1.95 to 0.52) 
Notes: Bold values are significant.  
Abbreviations: ß (95% CI): Beta coefficient (95% confidence interval); LIPA: light intensity physical 
activity; MVPA: moderate to vigorous physical activity; SB: sedentary behavior; TAC: Total activity 
counts. 
Model 1: adjusted for age, gender, race, education, accelerometer wear time 
Model 2: model 1 + lifestyle factors (BMI, smoking status) 
Model 3: model 2 + chronic health conditions (diabetes, hypertension, history of cardiovascular disease, 
history of cancer) 
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Table 14: Linear regression associations of physical behavior pattern metrics with 
handgrip strength by gender 
  
Handgrip strength (kg)  
ß (95% CI) 
  Men (n = 64) Women (n = 81) 
Physical behavior patterns     
MVPA <10 minute bouts (per 5 minutes higher)     
Model 1 0.47 (-0.30 to 1.23) 0.65 (-0.08 to 1.38) 
Model 2 0.55 (-0.23 to 1.33) 0.61 (-0.14 to 1.35) 
Model 3 0.46 (-0.30 to 1.23) 0.57 (-0.20 to 1.34) 
MVPA ≥10 minute bouts (per 5 minutes higher)     
Model 1 1.68 (-0.01 to 3.37) 2.25 (-1.55 to 6.06) 
Model 2 1.67 (-0.03 to 3.37) 2.09 (-1.83 to 6.01) 
Model 3 1.14 (-0.58 to 2.86) 2.70 (-1.30 to 6.70) 
Number of sedentary breaks (No. of breaks/day)     
Model 1 -0.01 (-0.09 to 0.06) 0.08 (0.00 to 0.15) 
Model 2 -0.01 (-0.09 to 0.07) 0.08 (0.00 to 0.15) 
Model 3 -0.01 (-0.09 to 0.06) -0.01 (-0.01 to 0.15) 
ASTP (per 0.1 ASTP)     
Model 1 -0.31 (-1.74 to 1.13) -0.49 (-1.46 to 0.47) 
Model 2 -0.37 (-1.82 to 1.08) -0.42 (-1.43 to 0.58) 
Model 3 -0.33 (-1.78 to 1.12) -0.33 (-1.28 to 0.87) 
Notes: Bold values are significant. The active-to-sedentary transition probability index is calculated by 
dividing the total number of breaks in sedentary behavior with the sum of minutes spent in physical 
activity. 
Abbreviations: ASTP: active-to-sedentary transition probability; ß (95% CI): Beta coefficient (95% 
confidence interval); MVPA: moderate to vigorous physical activity. 
Model 1: adjusted for age, gender, race, education, accelerometer wear time 
Model 2: model 1 + lifestyle factors (BMI, smoking status) 
Model 3: model 2 + chronic health conditions (diabetes, hypertension, history of cardiovascular disease, 
history of cancer) 
4.1.4 Dose-Response Associations of Physical Behavior Metrics with Probable 
Sarcopenia 
Volumes: Dose-response associations of physical behavior volume metrics with 
the odds of probable sarcopenia specified by EWGSOP2 are presented in Table 15. 
Participants who accumulated at least 10 minutes of total MVPA had 26% (95% CI 0.62 
to 0.89) lower odds of probable sarcopenia compared to the reference group of 
participants accumulating less than 5 minutes per day of total MVPA volumes in the fully 
adjusted model. There were no significant associations across tertiles of total activity 
counts, LIPA, and SB with probable sarcopenia. 
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Table 15: Dose-response associations of physical behavior volume metrics with 
probable sarcopenia 
Dose-response associations of TAC tertiles with probable sarcopenia 
  Total TAC (mean/SD) 
  First Tertile Second Tertile Third Tertile 
n 49 48 48 
TAC, mean (SD) 144,307 (43,221) 232,572 (21,296) 357,901 (85,911) 
Probable sarcopenia (yes/no)       
Model 1 Ref 1.02 (0.84 to 1.24) 0.90 (0.74 to 1.10) 
Model 2 Ref 1.01 (0.84 to 1.23) 0.89 (0.73 to 1.09) 
Model 3 Ref 1.01 (0.83 to 1.23) 0.88 (0.71 to 1.08) 
        
Dose-response associations of total MVPA groups with probable sarcopenia 
  Total MVPA (min/day) 
  0-5 min Group 5-10 min Group ≥10 min Group 
n 67 34 44 
MVPA, mean (SD) 2.7 (1.1) 7.1 (1.4) 21.9 (11.1) 
Probable sarcopenia (yes/no)       
Model 1 Ref 0.91 (0.76 to 1.11) 0.73 (0.61 to 0.88) 
Model 2 Ref 0.92 (0.76 to 1.11) 0.74 (0.62 to 0.89) 
Model 3 Ref 0.91 (0.75 to 1.12) 0.74 (0.62 to 0.89) 
        
Dose-response associations of total LIPA tertiles with probable sarcopenia 
  Total LIPA (min/day) 
  First Tertile Second Tertile Third Tertile 
n 49 48 48 
LIPA, mean (SD) 92.2 (29.3) 148.7 (13.4) 214.3 (42.5) 
Probable sarcopenia (yes/no)       
Model 1 Ref 0.96 (0.80 to 1.17) 0.90 (0.74 to 1.09) 
Model 2 Ref 0.96 (0.80 to 1.17) 0.91 (0.75 to 1.11) 
Model 3 Ref 0.97 (0.80 to 1.18) 0.91 (0.74 to 1.11) 
        
Dose-response associations of total SB tertiles with probable sarcopenia 
  Total SB (min/day) 
  First Tertile Second Tertile Third Tertile 
n 49 48 48 
SB, mean (SD) 577.4 (54.1) 662.7 (21.6) 822.0 (122.3) 
Probable sarcopenia (yes/no)       
Model 1 Ref 1.02 (0.83 to 1.24) 1.20 (0.93 to 1.53) 
Model 2 Ref 1.03 (0.84 to 1.26) 1.21 (0.94 to 1.55) 
Model 3 Ref 1.02 (0.83 to 1.25) 1.21 (0.94 to 1.57) 
Notes: Bold values are significant. Probable or confirmed sarcopenia will be defined using low upper limb 
muscle strength evaluated by a calibrated handgrip dynamometer (grip strength: <27 kg for men and <16 kg 
for women). 
Abbreviations: LIPA: light intensity physical activity; MVPA: moderate to vigorous physical activity; OR 
(95% CI): odds ratio (95% confidence interval); Ref: Reference; SB: sedentary behavior; TAC: Total activity 
counts. 
Model 1: adjusted for age, gender, race, education, accelerometer wear time 
Model 2: model 1 + lifestyle factors (BMI, smoking status) 
Model 3: model 2 + chronic health conditions (diabetes, hypertension, history of cardiovascular disease, 
history of cancer) 
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Patterns: Table 16 illustrates dose-response associations of physical behavior 
pattern metrics with the odds of probable sarcopenia defined by EWGSOP2 in the 
primary sample. The highest tertile of accumulated minutes in short MVPA bouts of less 
than 10 minutes also demonstrated a 22% (95% CI 0.64 to 0.95) lower likelihood for 
probable sarcopenia, compared to the lowest tertile of short MVPA bouts (<10 minutes) 
following final adjustment. Likewise, the odds of probable sarcopenia were 22% (95% CI 
0.63 to 0.98, model 3) lower among participants who had any minutes spent in long 
MVPA bouts of at least 10 minutes compared to participants who had zero accumulated 
time in long MVPA bouts (≥10 minutes). The study results also indicated no significant 




Table 16: Dose-response associations of physical behavior pattern metrics with 
probable sarcopenia 
Dose-response associations of short MVPA bouts (<10 minutes) duration tertiles with probable sarcopenia 
  MVPA <10 minute bout (min/day) 
  First Tertile Second Tertile Third Tertile 
n 49 48 48 
MVPA <10 minute bout, mean (SD) 2.2 (0.9) 5.6 (9.5) 17.8 (9.8) 
Probable sarcopenia (yes/no)       
Model 1 Ref 0.90 (0.75 to 1.09) 0.77 (0.63 to 0.93) 
Model 2 Ref 0.89 (0.74 to 1.08) 0.77 (0.64 to 0.94) 
Model 3 Ref 0.89 (0.74 to 1.08) 0.78 (0.64 to 0.95) 
        
Dose-response associations of long MVPA bouts (≥10 minutes) duration groups with probable sarcopenia 
  MVPA ≥10 minute bout (min/day)   
  No ≥10 minute bouts ≥10 minute bouts   
n 124 21   
MVPA ≥10 minute bout, mean (SD) 0.0 (0.0) 7.3 (5.3)   
Probable sarcopenia (yes/no)       
Model 1 Ref 0.77 (0.62 to 0.96)   
Model 2 Ref 0.78 (0.62 to 0.97)   
Model 3 Ref 0.78 (0.63 to 0.98)   
        
Dose-response associations of number of sedentary breaks tertiles with probable sarcopenia 
  Number of sedentary breaks (no. of breaks/day) 
  First Tertile Second Tertile Third Tertile 
n 49 48 48 
Sedentary breaks, mean (SD) 50.4 (12.4) 70.2 (3.8) 88.2 (13.4) 
Probable sarcopenia (yes/no)       
Model 1 Ref 1.04 (0.86 to 1.26) 0.92 (0.76 to 1.13) 
Model 2 Ref 1.04 (0.86 to 1.26) 0.92 (0.75 to 1.12) 
Model 3 Ref 1.03 (0.85 to 1.26) 0.91 (0.74 to 1.12) 
        
Dose-response associations of ASTP tertiles with probable sarcopenia 
  ASTP 
  First Tertile Second Tertile Third Tertile 
n 49 48 48 
ASTP, mean (SD) 0.35 (0.05) 0.47 (0.03) 0.59 (0.07) 
Probable sarcopenia (yes/no)       
Model 1 Ref 1.15 (0.94 to 1.40) 1.21 (1.00 to 1.47) 
Model 2 Ref 1.14 (0.94 to 1.38) 1.19 (0.98 to 1.45) 
Model 3 Ref 1.14 (0.93 to 1.40) 1.18 (0.97 to 1.44) 
Notes: Bold values are significant. Probable sarcopenia is defined using low upper limb muscle strength 
evaluated by a calibrated handgrip dynamometer (grip strength: <27 kg for men and <16 kg for women). The 
active-to-sedentary transition probability index is calculated by dividing the total number of breaks in sedentary 
behavior with the sum of minutes spent in physical activity. 
Abbreviations: ASTP: active-to-sedentary transition probability; MVPA: moderate to vigorous physical activity; 
OR (95% CI): odds ratio (95% confidence interval); Ref: Reference. 
Model 1: adjusted for age, gender, race, education, accelerometer wear time 
Model 2: model 1 + lifestyle factors (BMI, smoking status) 




4.2.1. Participant Characteristics 
The subsample included 87 participants with valid measurements of handgrip 
strength, DXA scans, gait speed, and accelerometry. Among them, 28 (32.2%) were 
classified as probable sarcopenic, 18 (20.7%) as confirmed sarcopenic, and 8 (9.2%) as 
severe sarcopenic according to the EWGSOP2 definition. The demographic and lifestyle 
factors of our subsample revealed mean values or frequencies similar to the primary 
sample. On average, participants in the subsample spent 9.1 (10.7) minutes per day or 
1.1% (1.2%) of the accelerometer wear time in MVPA, 148.4 (54.0) minutes per day or 
17.9% (6.9%) in LIPA, and 684.3 (139.4) minutes per day or 81.0% (7.7%) in SB. The 
mean of sarcopenia-relevant metrics, including handgrip strength (men: 29.2 (6.6) kg, 
women: 18.4 (5.5) kg), appendicular lean mass (men: 21.6 (2.7) kg, women: 15.3 (2.9) 
kg), and gait speed (0.96 (0.24) m/s), are reported in Table 17. 
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Table 17: Participant characteristics of the subsample 
  
Total sample 
(n = 87) 
Nonsarcopenic 
(n = 59) 
Probable sarcopenic 
(n = 28) 
Confirmed sarcopenic 
(n = 18) 
Severe sarcopenic 
(n = 8) 
Demographic factors      
Age, years, mean (SD) 88.2 (2.5) 88.2 (2.8) 88.4 (2.0) 87.9 (2.1) 87.9 (1.6) 
Women, n (%) 48 (55.2%) 34 (57.6%) 14 (50.0%) 11 (61.1%) 5 (62.5%) 
Race, n (%), black 27 (31.0%) 23 (39.0%) 4 (14.3%) 3 (16.7%) 2 (25.0%) 
Education, n (%), postsecondary 53 (60.9%) 34 (57.6%) 19 (67.9%) 14 (77.8%) 6 (75.0%) 
Site, n (%), Memphis 87 (100.0%) 59 (100.0%) 28 (100.0%) 18 (100.0%) 8 (100.0%) 
       
Lifestyle factors      
BMI (kg/m2), mean (SD) 26.6 (4.3) 27.3 (4.6) 25.2 (3.3) 24.1 (3.2) 24.4 (3.6) 
Current smoker, n (%) 4 (4.6%) 2 (3.4%) 2 (7.1%) 2 (11.1%) 1 (12.5%) 
       
Chronic health conditions      
Diabetes, n (%) 20 (23.0%) 13 (22.0%) 7 (25.0%) 5 (27.8%) 3 (37.5%) 
Hypertension, n (%) 63 (72.4%) 41 (69.5%) 22 (78.6%) 15 (83.3%) 8 (100.0%) 
History of cardiovascular disease, n (%) 28 (32.2%) 19 (32.2%) 9 (32.1%) 5 (27.8%) 4 (50.0%) 
History of cancer, n (%) 27 (31.0%) 20 (33.9%) 7 (25.0%) 3 (16.7%) 2 (25.0%) 
       
Muscle strength      
Handgrip strength (kg), mean (SD) 23.3 (8.0) 26.1 (7.2) 17.2 (6.0) 15.8 (6.2) 16.9 (5.5) 
Handgrip strength men (kg), mean (SD) 29.2 (6.6) 33.1 (4.2) 22.3 (3.3) 22.1 (3.9) 22.8 (3.0) 
Handgrip strength women (kg), mean 
(SD) 
18.4 (5.5) 21.0 (3.9) 12.1 (3.0) 11.8 (3.3) 13.3 (2.4) 
       
DXA-acquired body composition 
measures 
     
Total body fat (%), mean (SD) 34.8 (6.7) 35.1 (6.9) 34.3 (6.2) 35.9 (5.5) 36.2 (4.4) 
Appendicular lean mass (kg),  
mean (SD) 
18.1 (4.2) 18.8 (4.1) 16.7 (4.0) 14.9 (3.2) 15.0 (3.2) 
Appendicular lean mass men (kg), 
mean (SD) 
21.6 (2.7) 22.4 (2.8) 20.2 (2.0) 18.6 (0.9) 18.7 (0.9) 
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Appendicular lean mass women (kg), 
mean (SD) 
15.3 (2.9) 16.2 (2.8) 13.2 (1.8) 12.5 (1.1) 12.7 (0.5) 
       
Physical performance      
Gait speed (m/s), mean (SD) 0.96 (0.24) 1.00 (0.24) 0.90 (0.23) 0.85 (0.23) 0.63 (0.10) 
       
Accelerometer      
Average minutes of weartime 
(min/day), mean (SD) 841.8 (126.7) 840.2 (124.2) 845.3 (134.1) 835.1 (101.0) 814.1 (110.4) 
TAC (counts/day), mean (SD) 245,687 (109,216) 248,125 (115,022) 240,549 (97,635) 225,578 (96,781) 203,376 (137,803) 
% time MVPA, median (IQR) 0.6 (0.3, 1.1) 0.7 (0.4, 1.7) 0.4 (0.3, 1.0) 0.4 (0.1, 0.8) 0.3 (0.2, 0.4) 
% time MVPA, mean (SD) 1.1 (1.2) 1.2 (1.3) 0.8 (1.1) 0.6 (0.5) 0.4 (0.3) 
% LIPA, mean (SD) 17.9 (6.9) 18.5 (7.2) 16.7 (6.2) 14.9 (5.5) 12.9 (5.7) 
% SB, mean (SD) 81.0 (7.7) 80.2 (8.1) 82.5 (6.8) 84.5 (5.7) 86.7 (5.8) 
MVPA (min/day), median (IQR) 4.9 (3.0, 11.3) 5.2 (3.2, 14.9) 3.4 (2.8, 7.4) 3.5 (3.0, 6.8) 3.0 (1.7, 3.5) 
MVPA (min/day), mean (SD) 9.1 (10.7) 10.3 (11.2) 6.6 (9.2) 4.9 (3.6) 3.0 (2.0) 
LIPA (min/day), mean (SD) 148.4 (54.0) 153.0 (57.0) 138.6 (46.5) 123.1 (41.2) 104.7 (45.8) 
SB (min/day), mean (SD) 684.3 (139.4) 676.9 (139.8) 700.0 (139.8) 707.2 (106.8) 706.4 (110.5) 
MVPA in bouts <10 min (min/day), 
median (IQR) 
0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 
MVPA in bouts <10 min (min/day), 
mean (SD) 
8.0 (8.7) 8.7 (8.5) 6.6 (9.2) 4.9 (3.6) 3.0 (2.0) 
MVPA in bouts ≥10 min (min/day), 
median (IQR) 4.9 (3.0, 9.6) 5.2 (3.2, 12.3) 3.4 (2.8, 7.4) 3.5 (3.0, 6.8) 3.0 (1.7, 3.5) 
MVPA in bouts ≥10 min (min/day), 
mean (SD) 
1.1 (3.7) 1.6 (4.4) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 
Number of sedentary breaks  
(No. of breaks/day), mean (SD) 
70.4 (17.0) 70.9 (17.2) 69.4 (16.9) 63.9 (15.9) 60.1 (20.8) 
ASTP, mean (SD) 0.48 (0.12) 0.48 (0.13) 0.50 (0.09) 0.52 (0.09) 0.58 (0.08) 
Notes: All data are mean +/- SD (independent samples t tests), except median (interquartile range) (Mann-Whitney U-tests) and proportions (chi-square test). The active-to-
sedentary transition probability index is calculated by dividing the total number of breaks in sedentary behavior with the sum of minutes spent in physical activity. 
Abbreviations: ASTP: active-to-sedentary transition probability; BMI: body mass index; LIPA: light intensity physical activity; MVPA: moderate to vigorous physical 
activity; SB: sedentary behavior; TAC: Total activity counts. 
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4.2.2 Associations of Physical Behavior Metrics with Sarcopenia Status (Binomial 
Logistic Regressions) 
Volumes: Table 18 demonstrates the odds ratios for the associations of physical 
behavior volume metrics with any sarcopenic status according to the EWGSOP2 
definition, including probable sarcopenia, confirmed sarcopenia, and severe sarcopenia, 
in the subsample.  
Probable sarcopenia: There were no significant associations of any physical 
behavior volume metric with probable sarcopenia.  
Confirmed sarcopenia: Each 5 minutes per day of MVPA higher was associated 
with a 49% (95% CI 0.26 to 0.98) lower likelihood for confirmed sarcopenia after 
adjusting for age, gender, race, education, and accelerometer wear time (model 1). 
Similarly, each 60 minutes higher of daily LIPA was associated with 55% (95% CI 0.22 
to 0.89) lower odds of confirmed sarcopenia in the same model (model 1). However, the 
associations of LIPA and MVPA with confirmed sarcopenia were attenuated and thus no 
longer significant after further adjusting for lifestyle factors (model 2) and chronic health 
conditions (model 3). Furthermore, each additional 60 minutes per day of SB volume was 
associated with 2.1 (95% CI 1.01 to 4.35) times higher odds of confirmed sarcopenia 
after full adjustment. No significant association was observed between total activity 
counts and confirmed sarcopenia.  
Severe sarcopenia: The odds for a severe sarcopenia diagnosis were 68% (95% CI 
0.11 to 0.91, model 2) lower following each 60 minutes more per day of LIPA but did not 
remain significant after full adjustment (model 3). Each additional 60 minutes per day 
spent in SB was associated with 3.18 (95% CI 1.13 to 8.92, model 2) times higher odds 
78 
of severe sarcopenia. However, the significance of this relationship was also attenuated 
and therefore no longer significant after adjusting for chronic health conditions (model 
3). In addition, there were no significant associations of total activity counts and MVPA 
with severe sarcopenia.  
Table 18: Odds ratios for the associations of physical behavior volume metrics with 
sarcopenia status 
  Dichotomous (yes/no) 
  
Probable sarcopenic 
OR (95 % CI) 
Confirmed sarcopenic  
OR (95% CI) 
Severe sarcopenic  
OR (95% CI) 
Physical behavior volumes       
TAC (per 1 SD (109,216 counts))     
Model 1 0.84 (0.51 to 1.38) 0.65 (0.34 to 1.24) 0.54 (0.21 to 1.43) 
Model 2 0.82 (0.49 to 1.36) 0.64 (0.33 to 1.26) 0.53 (0.19 to 1.47) 
Model 3 0.85 (0.49 to 1.46) 0.57 (0.27 to 1.21) 0.54 (0.17 to 1.70) 
Total MVPA (per 5 minutes higher)      
Model 1 0.74 (0.54 to 1.02) 0.51 (0.26 to 0.98) 0.10 (0.01 to 1.13) 
Model 2 0.75 (0.54 to 1.02) 0.52 (0.26 to 1.02) 0.06 (0.00 to 1.10) 
Model 3 0.75 (0.54 to 1.05) 0.48 (0.23 to 1.00) 0.02 (0.00 to 1.17) 
Total LIPA (per 60 minutes higher)      
Model 1 0.77 (0.45 to 1.32) 0.45 (0.22 to 0.89) 0.30 (0.11 to 0.82) 
Model 2 0.83 (0.48 to 1.43) 0.50 (0.24 to 1.03) 0.32 (0.11 to 0.91) 
Model 3 0.89 (0.49 to 1.58) 0.47 (0.21 to 1.04) 0.27 (0.07 to 1.07) 
Total SB (per 60 minutes higher)      
Model 1 1.35 (0.82 to 2.20) 2.19 (1.15 to 4.18) 3.23 (1.23 to 8.47) 
Model 2 1.27 (0.77 to 2.08) 1.99 (1.01 to 3.89) 3.18 (1.13 to 8.92) 
Model 3 1.20 (0.71 to 2.02) 2.10 (1.01 to 4.35) 3.79 (0.99 to 14.56) 
Notes: Bold values are significant. Probable or confirmed sarcopenia will be defined using low upper limb 
muscle strength evaluated by a calibrated handgrip dynamometer (grip strength: <27 kg for men and <16 kg 
for women), low muscle mass tested by a dual-energy X-ray absorptiometry (appendicular skeletal muscle 
mass: <20 kg for men and <15 kg for women), and low physical performance assessed by a 20-m usual 
walking speed test (gait speed: ≤0.8 m/s). 
Abbreviations: LIPA: light intensity physical activity; MVPA: moderate to vigorous physical activity; OR 
(95% CI): odds ratio (95% confidence interval); SB: sedentary behavior; TAC: Total activity counts. 
Model 1: adjusted for age, gender, race, education, accelerometer wear time 
Model 2: model 1 + lifestyle factors (BMI, smoking status) 
Model 3: model 2 + chronic health conditions (diabetes, hypertension, history of cardiovascular disease, 
history of cancer) 
 
Patterns: Table 19 shows the odds ratios for the associations of physical behavior 
pattern metrics with any sarcopenic status according to the EWGSOP2 definition, 
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including probable sarcopenia, confirmed sarcopenia, and severe sarcopenia, in the 
subsample. 
Probable sarcopenia: All physical behavior pattern metrics, including short 
MVPA bouts (<10 minutes), long MVPA bouts (≥10 minutes), total number of sedentary 
breaks, and ASTP, showed non-significant associations with probable sarcopenia. 
Confirmed sarcopenia: There were no significant associations of any physical 
behavior pattern metric with confirmed sarcopenia. 
Severe sarcopenia: Each 0.1 ASTP higher was associated with 2.9 (95% CI 1.05 
to 8.02) times higher odds of severe sarcopenia in the fully adjusted model 3. Other PA 
pattern metrics, including short MVPA bouts (<10 minutes), long MVPA bouts (≥10 
minutes), and sedentary breaks, were not associated with severe sarcopenia.  
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Table 19: Odds ratios for the associations of physical behavior pattern metrics with 
sarcopenia status 
  Dichotomous (yes/no) 
  
Probable sarcopenic 
OR (95 % CI) 
Confirmed sarcopenic  
OR (95% CI) 
Severe sarcopenic  
OR (95% CI) 
Physical behavior patterns       
MVPA <10 minute bouts (per 5 minutes higher)     
Model 1 0.80 (0.57 to 1.12) 0.49 (0.24 to 1.00) 0.09 (0.01 to 1.02) 
Model 2 0.80 (0.57 to 1.11) 0.51 (0.25 to 1.05) 0.05 (0.00 to 1.00) 
Model 3 0.81 (0.57 to 1.15) 0.47 (0.22 to 1.01) 0.02 (0.00 to 1.09) 
MVPA ≥10 minute bouts (per 5 minutes higher)      
Model 1 N/A N/A N/A 
Model 2 N/A N/A N/A 
Model 3 N/A N/A N/A 
Number of sedentary breaks (No. of breaks/day)      
Model 1 1.00 (0.97 to 1.03) 0.97 (0.94 to 1.00) 0.96 (0.92 to 1.01) 
Model 2 1.00 (0.97 to 1.03) 0.97 (0.94 to 1.01) 0.96 (0.92 to 1.01) 
Model 3 1.01 (0.97 to 1.04) 0.97 (0.93 to 1.01) 0.96 (0.91 to 1.02) 
ASTP (per 0.1 ASTP)       
Model 1 1.27 (0.84 to 1.91) 1.51 (0.94 to 2.43) 2.30 (1.17 to 4.50) 
Model 2 1.23 (0.81 to 1.87) 1.50 (0.89 to 2.50) 2.47 (1.19 to 5.15) 
Model 3 1.16 (0.75 to 1.80) 1.43 (0.82 to 2.48) 2.90 (1.05 to 8.02) 
Notes: Bold values are significant. Probable or confirmed sarcopenia will be defined using low upper limb 
muscle strength evaluated by a calibrated handgrip dynamometer (grip strength: <27 kg for men and <16 kg for 
women), low muscle mass tested by a dual-energy X-ray absorptiometry (appendicular skeletal muscle mass: 
<20 kg for men and <15 kg for women), and low physical performance assessed by a 20-m usual walking speed 
test (gait speed: ≤0.8 m/s). The active-to-sedentary transition probability index is calculated by dividing the 
total number of breaks in sedentary behavior with the sum of minutes spent in physical activity. 
Abbreviations: ASTP: active-to-sedentary transition probability; MVPA: moderate to vigorous physical 
activity; OR (95% CI): odds ratio (95% confidence interval). 
Model 1: adjusted for age, gender, race, education, accelerometer wear time 
Model 2: model 1 + lifestyle factors (BMI, smoking status) 
Model 3: model 2 + chronic health conditions (diabetes, hypertension, history of cardiovascular disease, history 
of cancer) 
4.2.3 Associations of Physical Behavior Metrics with Sarcopenia-Relevant 
Components (Multivariate Linear Regressions by Gender) 
Volumes: Table 20 illustrates multivariate linear regression outcomes by gender 
of the subsample on associations of physical behavior volume metrics with sarcopenia-
related parameters including handgrip strength, appendicular lean mass, and gait speed. 
Handgrip strength: There were no significant associations of handgrip strength 
with any physical behavior volume metric in the subsample.  
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Appendicular lean mass: Among women, each 60 minutes per day higher SB was 
associated with lower appendicular lean mass (ß=-0.66, 95% CI -1.31 to -0.01) after 
adjusting for age, gender, race, education, and accelerometer wear time (model 1) but did 
not remain significant after further adjustments for lifestyle factors (model 2) and chronic 
health conditions (model 3). Total activity counts, LIPA, and MVPA were not associated 
with appendicular lean mass in women. Men demonstrated non-significant associations 
across all physical behavior volume metrics, including total activity counts, MVPA, 
LIPA, and SB, with appendicular lean mass. 
Gait speed: Gait speed was significantly better among men for each SD (109,216 
counts) higher total activity counts (ß=0.09, 95% CI 0.01 to 0.17), each 5 minutes higher 
MVPA (ß=0.03, 95% CI 0.01 to 0.06), and each 60 minutes higher LIPA (ß=0.15, 95% 
CI 0.06 to 0.24) across all models. Higher volumes of SB demonstrated a non-significant 
association with gait speed in men. Among women, higher total activity counts per 1 SD 
(109,216 counts) showed associations with better gait speed in model 2 (ß=0.07, 95% CI 
0.01 to 0.14) but lacked significance in model 3. Likewise, each 60 minutes more in 
LIPA was associated with higher gait speed (ß=0.12, 95% CI 0.05 to 0.18, model 2) and 
every 60 minutes more in SB was associated with lower gait speed (ß=-0.10, 95% CI -
0.16 to -0.04, model 2) in women but did not remain significant after full adjustment. 
Total volumes of MVPA were not associated with gait speed among women. 
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Table 20: Linear regression associations of physical behavior volume metrics with sarcopenia-relevant components by gender 
  
Handgrip strength (kg)  
ß (95% CI) 
Appendicular lean mass (kg) 
ß (95% CI) 
Gait speed (m/s) 
ß (95% CI) 
  Men (n = 39) Women (n = 48) Men (n = 39) Women (n = 48) Men (n = 39) Women (n = 48) 
Physical behavior volumes             
TAC (per 1 SD (109,216 counts))            
Model 1 0.64 (-1.64 to 2.91) 0.33 (-1.23 to 1.90) 0.08 (-0.86 to 1.02) 0.36 (-0.37 to 1.08) 0.09 (0.02 to 0.16) 0.07 (0.01 to 0.14) 
Model 2 0.71 (-1.63 to 3.05) 0.34 (-1.15 to 1.82) 0.36 (-0.45 to 1.16) 0.36 (-0.18 to 0.90) 0.09 (0.02 to 0.16) 0.07 (0.01 to 0.14) 
Model 3 0.03 (-2.30 to 2.35) -0.26 (-1.93 to 1.41) 0.17 (-0.65 to 0.99) 0.33 (-0.30 to 0.95) 0.09 (0.01 to 0.17) 0.03 (-0.04 to 0.10) 
Total MVPA (per 5 minutes higher)            
Model 1 0.59 (-0.22 to 1.41) 0.53 (-0.61 to 1.68) -0.04 (-0.39 to 0.30) 0.24 (-0.30 to 0.77) 0.03 (0.01 to 0.06) 0.04 (-0.01 to 0.09) 
Model 2 0.60 (-0.22 to 1.43) 0.34 (-0.76 to 1.44) -0.01 (-0.31 to 0.28) 0.07 (-0.34 to 0.48) 0.03 (0.01 to 0.06) 0.04 (-0.01 to 0.09) 
Model 3 0.36 (-0.46 to 1.19) 0.13 (-1.07 to 1.34) -0.04 (-0.34 to 0.25) 0.03 (-0.43 to 0.49) 0.03 (0.01 to 0.06) 0.01 (-0.04 to 0.06) 
Total LIPA (per 60 minutes higher)            
Model 1 -0.12 (-2.93 to 2.69) 0.92 (-0.64 to 2.48) 0.03 (-1.13 to 1.18) 0.75 (0.04 to 1.45) 0.13 (0.04 to 0.21) 0.11 (0.05 to 0.17) 
Model 2 -0.08 (-2.95 to 2.79) 0.50 (-1.04 to 2.04) 0.25 (-0.74 to 1.24) 0.39 (-0.17 to 0.95) 0.13 (0.04 to 0.21) 0.12 (0.05 to 0.18) 
Model 3 -0.81 (-3.96 to 2.06) -0.10 (-1.90 to 1.71) 0.35 (-0.66 to 1.37) 0.37 (-0.31 to 1.05) 0.15 (0.06 to 0.24) 0.07 (0.00 to 0.15) 
Total SB (per 60 minutes higher)            
Model 1 -0.31 (-2.65 to 2.04) -0.84 (-2.27 to 0.58) 0.01 (-0.96 to 0.97) -0.66 (-1.31 to -0.01) -0.11 (-0.18 to 0.04) -0.10 (-0.16 to -0.04) 
Model 2 -0.34 (-2.73 to 2.05) -0.46 (-1.87 to 0.95) -0.16 (-0.99 to 0.66) -0.33 (-0.85 to 0.18) -0.11 (-0.18 to 0.04) -0.10 (-0.16 to -0.04) 
Model 3 0.31 (-2.09 to 2.71) 0.06 (-1.59 to 1.71) -0.21 (-1.06 to 0.63) -0.31 (-0.93 to 0.31) -0.13 (-0.20 to 0.05) -0.06 (-0.13 to 0.00) 
Notes: Bold values are significant.  
Abbreviations: ß (95% CI): Beta coefficient (95% confidence interval); LIPA: light intensity physical activity; MVPA: moderate to vigorous physical activity; SB: sedentary 
behavior; TAC: Total activity counts. 
Model 1: adjusted for age, gender, race, education, accelerometer wear time 
Model 2: model 1 + lifestyle factors (BMI, smoking status) 
Model 3: model 2 + chronic health conditions (diabetes, hypertension, history of cardiovascular disease, history of cancer) 
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Patterns: Table 21 depicts multivariate linear regression outcomes by gender of 
the subsample on associations of physical behavior pattern metrics with sarcopenia-
related indicators including handgrip strength, appendicular lean mass, and gait speed. 
Handgrip strength: There were no significant associations of handgrip strength 
with any physical behavior pattern metric in the subsample. 
Appendicular lean mass: A higher number of sedentary breaks was associated 
with higher appendicular lean mass (ß=0.05, 95% CI 0.01 to 0.09) among women in the 
fully adjusted model. There were no significant associations of short MVPA bouts (<10 
minutes), long MVPA bouts (≥10 minutes), and ASTP with appendicular lean mass in 
women. On the other hand, all analyzed PA pattern metrics, including short MVPA bouts 
(<10-minutes), long MVPA bouts (≥10 minutes), sedentary breaks, and ASTP, showed 
non-significant associations with appendicular lean mass among men.  
Gait speed: Each additional 5 minutes spent in short MVPA bouts (<10 minutes) 
among men was associated with faster gait speed in model 2 (ß=0.04, 95% CI 0.01 to 
0.07) but attenuated after final adjustment. No relationship was observed between higher 
levels of short MVPA bouts (<10 minutes) and gait speed among women. Furthermore, 
men and women significantly lowered gait speed per each added 0.1 ASTP (men: ß=-
0.14, 95% CI -0.20 to -0.08, women: ß=-0.07, 95% CI -0.12 to -0.02) in the fully adjusted 
model. On the other hand, long MVPA bouts (≥10 minutes) and sedentary breaks were 
not associated with gait speed in men and women. 
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Table 21: Linear regression associations of physical behavior pattern metrics with sarcopenia-relevant components by gender 
  
Handgrip strength (kg)  
ß (95% CI) 
Appendicular lean mass (kg) 
ß (95% CI) 
Gait speed (m/s) 
ß (95% CI) 
  Men (n = 39) Women (n = 48) Men (n = 39) Women (n = 48) Men (n = 39) Women (n = 48) 
Physical behavior patterns             
MVPA <10 minute bouts (per 5 minutes higher)           
Model 1 0.51 (-0.52 to 1.54) 0.56 (-0.62 to 1.74) -0.04 (-0.47 to 0.39) 0.23 (-0.33 to 0.78) 0.04 (0.01 to 0.07) 0.05 (0.00 to 0.10) 
Model 2 0.54 (-0.52 to 1.59) 0.44 (-0.68 to 1.57) 0.06 (-0.31 to 0.43) 0.12 (-0.29 to 0.54) 0.04 (0.01 to 0.07) 0.05 (0.00 to 0.11) 
Model 3 0.30 (-0.73 to 1.34) 0.19 (-1.06 to 1.45) 0.01 (-0.36 to 0.38) 0.08 (-0.40 to 0.56) 0.00 (0.00 to 0.08) 0.02 (-0.03 to 0.07) 
MVPA ≥10 minute bouts (per 5 minutes higher)            
Model 1 N/A N/A N/A N/A N/A N/A 
Model 2 N/A N/A N/A N/A N/A N/A 
Model 3 N/A N/A N/A N/A N/A N/A 
Number of sedentary breaks (No. of breaks/day)            
Model 1 -0.07 (-0.21 to 0.06) 0.07 (-0.03 to 0.16) 0.01 (-0.05 to 0.07) 0.07 (0.03 to 0.11) 0.00 (0.00 to 0.01) 0.01 (0.00 to 0.01) 
Model 2 -0.07 (-0.21 to 0.07) 0.04 (-0.05 to 0.13) 0.02 (-0.03 to 0.07) 0.05 (0.02 to 0.08) 0.00 (0.00 to 0.01) 0.01 (0.00 to 0.01) 
Model 3 -0.10 (-0.23 to 0.04) 0.01 (-0.10 to 0.11) 0.02 (-0.03 to 0.07) 0.05 (0.01 to 0.09) 0.00 (0.00 to 0.01) 0.00 (0.00 to 0.01) 
ASTP (per 0.1 ASTP)             
Model 1 -0.02 (-2.13 to 2.09) -0.60 (-1.86 to 0.65) 0.35 (-0.51 to 1.21) -0.39 (-0.97 to 0.19) -0.12 (-0.17 to -0.06) -0.10 (-0.14 to -0.05) 
Model 2 -0.04 (-2.19 to 2.10) -0.36 (-1.58 to 0.86) 0.23 (-0.51 to 0.97) -0.18 (-0.63 to 0.27) -0.12 (-0.18 to -0.06) -0.10 (-0.15 to -0.05) 
Model 3 0.46 (-1.72 to 2.64) -0.00 (-1.37 to 1.36) 0.06 (-0.72 to 0.83) -0.17 (-0.69 to 0.35) -0.14 (-0.20 to -0.08) -0.07 (-0.12 to -0.02) 
Notes: Bold values are significant. The active-to-sedentary transition probability index is calculated by dividing the total number of breaks in sedentary behavior with the sum of 
minutes spent in physical activity. 
Abbreviations: ß (95% CI): ASTP: active-to-sedentary transition probability; Beta coefficient (95% confidence interval); MVPA: moderate to vigorous physical activity; N/A: 
Not available. 
Model 1: adjusted for age, gender, race, education, accelerometer wear time 
Model 2: model 1 + lifestyle factors (BMI, smoking status) 
Model 3: model 2 + chronic health conditions (diabetes, hypertension, history of cardiovascular disease, history of cancer) 
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4.2.4 Dose-Response Associations of Physical Behavior Metrics with Sarcopenia 
Status 
Volumes: The outcomes of the subsample regarding the dose-response 
associations of physical behavior volume metrics with EWGSOP2 defined sarcopenic 
status, including probable sarcopenia, confirmed sarcopenia, and severe sarcopenia, are 
illustrated in Table 22. 
Probable sarcopenia: In contrast to individuals who provided 0-5 minutes per day 
of total volume of MVPA, participants with at least 10 minutes per day of total MVPA 
showed significant lower odds of probable sarcopenia (OR=0.77, 95% CI 0.61 to 0.98, 
model 2). There were no significant associations across tertiles of total activity counts, 
LIPA, and SB with probable sarcopenia. 
Confirmed sarcopenia: Participants in the highest tertile of total activity counts 
had significantly lower odds of confirmed sarcopenia (OR=0.81, 95% CI 0.66 to 0.99, 
model 2) when compared to participants in the lowest tertile. Model 1 and model 3 
presented non-significant results of this association. The likelihood for a confirmed 
sarcopenia diagnosis was significantly lower among participants who spent at least 10 
minutes per day in total volumes of MVPA (OR=0.79, 95% CI 0.65 to 0.97, model 2) 
compared to the group of individuals who engaged in less than 5 minutes per day of total 
MVPA. Similarly, participants in the highest tertile of LIPA had significantly lower odds 
of confirmed sarcopenia (OR=0.80, 95% CI 0.66 to 0.98, model 2) when compared to the 
lowest tertile of LIPA. However, after adjusting for chronic health conditions (model 3), 
the associations of MVPA and LIPA with confirmed sarcopenia were no longer 
significant. In comparison to individuals among the lowest tertile of SB (least sedentary 
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group), participants in the highest tertile of SB (most sedentary group) indicated 1.41 
(95% CI 0.91 to 1.41) higher odds of confirmed sarcopenia in the fully adjusted model.  
Severe sarcopenia: Individuals among the highest tertile of total activity counts 
had a significantly lower likelihood for severe sarcopenia (OR=0.85, 95% CI 0.73 to 
0.99) in contrast to participants among the lowest tertile of total activity counts. Model 1 
and model 3, however, demonstrated non-significant results of this association. The odds 
for severe sarcopenia were significantly lower among participants who spent 10 minutes 
or more per day in total MVPA (OR=0.85, 95% CI 0.73 to 0.99, model 2) compared to 
individuals with less than 5 minutes per day of total MVPA. Participants in the highest 
tertile of LIPA also demonstrated a significant association with severe sarcopenia 
(OR=0.85, 95% CI 0.73 to 0.99, model 2) when compared with participants among the 
lowest tertile of LIPA. The adjustment for comorbid conditions (model 3), however, 
attenuated the significance regarding the associations of MVPA and LIPA with severe 




Table 22: Dose-response associations of physical behavior volume metrics with 
sarcopenia status 
Dose-response associations of TAC tertiles with sarcopenia status  
  Total TAC (mean/SD) 
  First Tertile Second Tertile Third Tertile 
n 29 29 29 
TAC, mean (SD) 145,877 (44,216) 226,888 (21,107) 364,295 (94,771) 
Probable sarcopenia (yes/no)      
Model 1 Ref 1.01 (0.79 to 1.29) 0.85 (0.66 to 1.09) 
Model 2 Ref 0.98 (0.77 to 1.25) 0.83 (0.65 to 1.06) 
Model 3 Ref 0.98 (0.77 to 1.26) 0.84 (0.66 to 1.08) 
Confirmed sarcopenia (yes/no)      
Model 1 Ref 0.99 (0.80 to 1.23) 0.83 (0.67 to 1.03) 
Model 2 Ref 0.95 (0.77 to 1.16) 0.81 (0.66 to 0.99) 
Model 3 Ref 0.95 (0.78 to 1.16) 0.82 (0.67 to 1.00) 
Severe sarcopenia (yes/no)      
Model 1 Ref 0.88 (0.76 to 1.03) 0.86 (0.74 to 1.00) 
Model 2 Ref 0.86 (0.74 to 1.01) 0.85 (0.73 to 0.99) 
Model 3 Ref 0.86 (0.74 to 1.01) 0.87 (0.74 to 1.01) 
    
Dose-response associations of total MVPA groups with sarcopenia status 
  Total MVPA (min/day) 
  0-5 min Group 5-10 min Group ≥10 min Group 
n 45 18 24 
MVPA, mean (SD) 2.8 (1.0) 7.0 (1.5) 22.5 (12.3) 
Probable sarcopenia (yes/no)      
Model 1 Ref 0.89 (0.69 to 1.16) 0.74 (0.59 to 0.94 
Model 2 Ref 0.90 (0.69 to 1.16) 0.77 (0.61 to 0.98) 
Model 3 Ref 0.89 (0.68 to 1.15) 0.79 (0.62 to 1.01) 
Confirmed sarcopenia (yes/no)      
Model 1 Ref 0.98 (0.78 to 1.22) 0.75 (0.61 to 0.92) 
Model 2 Ref 0.98 (0.79 to 1.21) 0.79 (0.65 to 0.97) 
Model 3 Ref 0.96 (0.77 to 1.19) 0.82 (0.67 to 1.00) 
Severe sarcopenia (yes/no)      
Model 1 Ref 0.88 (0.75 to 1.03) 0.83 (0.72 to 0.97) 
Model 2 Ref 0.88 (0.74 to 1.03) 0.85 (0.73 to 0.99) 
Model 3 Ref 0.87 (0.74 to 1.03) 0.88 (0.75 to 1.02) 
    
Dose-response associations of total LIPA tertiles with sarcopenia status 
  Total LIPA (min/day) 
  First Tertile Second Tertile Third Tertile 
n 29 29 29 
LIPA, mean (SD) 92.3 (30.2) 147.6 (11.7) 205.3 (35.7) 
Probable sarcopenia (yes/no)      
Model 1 Ref 0.91 (0.71 to 1.16) 0.88 (0.69 to 1.12) 
Model 2 Ref 0.90 (0.71 to 1.15) 0.90 (0.71 to 1.15) 
Model 3 Ref 0.92 (0.72 to 1.18) 0.92 (0.72 to 1.19) 
Confirmed sarcopenia (yes/no)      
Model 1 Ref 0.94 (0.76 to 1.15) 0.78 (0.63 to 0.95) 
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Model 2 Ref 0.93 (0.76 to 1.13) 0.80 (0.66 to 0.98) 
Model 3 Ref 0.96 (0.78 to 1.17) 0.82 (0.67 to 1.00) 
Severe sarcopenia 
(yes/no)       
Model 1 Ref 0.93 (0.80 to 1.08) 0.84 (0.72 to 0.97) 
Model 2 Ref 0.92 (0.79 to 1.08) 0.85 (0.73 to 0.99) 
Model 3 Ref 0.94 (0.80 to 1.09) 0.87 (0.75 to 1.01) 
    
Dose-response associations of total SB tertiles with sarcopenia status 
  Total SB (min/day) 
  First Tertile Second Tertile Third Tertile 
n 29 29 29 
SB, mean (SD) 567.5 (46.0) 651.3 (26.8) 834.2 (135.3) 
Probable sarcopenia (yes/no)      
Model 1 Ref 0.99 (0.76 to 1.29) 1.20 (0.86 to 1.67) 
Model 2 Ref 0.96 (0.73 to 1.25) 1.17 (0.83 to 1.64) 
Model 3 Ref 0.91 (0.69 to 1.20) 1.14 (0.80 to 1.61) 
Confirmed sarcopenia (yes/no)      
Model 1 Ref 1.13 (0.91 to 1.42) 1.47 (1.10 to 1.95) 
Model 2 Ref 1.09 (0.88 to 1.35) 1.43 (1.09 to 1.88) 
Model 3 Ref 1.06 (0.85 to 1.33) 1.41 (1.06 to 1.86) 
Severe sarcopenia (yes/no)      
Model 1 Ref 1.15 (0.98 to 1.36) 1.19 (0.97 to 1.47) 
Model 2 Ref 1.13 (0.96 to 1.34) 1.18 (0.96 to 1.46) 
Model 3 Ref 1.09 (0.92 to 1.30) 1.13 (0.91 to 1.41) 
Notes: Bold values are significant. Probable or confirmed sarcopenia will be defined using low 
upper limb muscle strength evaluated by a calibrated handgrip dynamometer (grip strength: <27 kg 
for men and <16 kg for women), low muscle mass tested by a dual-energy X-ray absorptiometry 
(appendicular skeletal muscle mass: <20 kg for men and <15 kg for women), and low physical 
performance assessed by a 20-m usual walking speed test (gait speed: ≤0.8 m/s). 
Abbreviations: LIPA: light intensity physical activity; MVPA: moderate to vigorous physical 
activity; OR (95% CI): odds ratio (95% confidence interval); Ref: Reference; SB: sedentary 
behavior; TAC: Total activity counts. 
Model 1: adjusted for age, gender, race, education, accelerometer wear time 
Model 2: model 1 + lifestyle factors (BMI, smoking status) 
Model 3: model 2 + chronic health conditions (diabetes, hypertension, history of cardiovascular 
disease, history of cancer) 
 
Patterns: Table 23 demonstrates the dose-response associations of physical 
behavior pattern metrics with sarcopenic status classified by EWGSOP2, including 
probable sarcopenia, confirmed sarcopenia, and severe sarcopenia, in the subsample. 
Probable sarcopenia: The group of participants with any time spent in long 
MVPA bouts (≥10 minutes) had 35% (95% CI 0.47 to 0.89) lower odds for a probable 
sarcopenia diagnosis compared to individuals who engaged zero time in long MVPA 
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bouts (≥10 minutes) after final adjustment. No significant associations were detected 
across tertiles of short MVPA bouts (<10 minutes), sedentary breaks, and ASTP with 
probable sarcopenia.  
Confirmed sarcopenia: The likelihood for a confirmed sarcopenia diagnosis was 
19% (95% CI 0.66 to 0.99, model 2) lower among participants in the highest tertile of 
short MVPA bouts (<10 minutes) compared to individuals in the lowest tertile of short 
MVPA bouts (<10 minutes). However, significant outcomes of this association were 
lacking in model 1 and model 3. There were also significant associations across tertiles of 
ASTP with confirmed sarcopenia in model 1 (second tertile: OR=1.24 95% CI 1.01 to 
1.52; third tertile: OR: 1.27 95% CI 1.03 to 1.57), but further adjustments for lifestyle 
factors (model 2) and chronic health conditions (model 3) attenuated the associations. 
There were no significant associations across tertiles of long MVPA bouts (≥10 minutes) 
and sedentary breaks with confirmed sarcopenia.  
Severe sarcopenia: Participants among the highest tertile of short MVPA bouts 
(<10 minutes) had 18% (95% CI 0.71 to 0.96) lower odds of severe sarcopenia compared 
to participants in the lowest tertile of short MVPA bouts (<10 minutes) after full 
adjustment. Furthermore, individuals in the highest tertile of ASTP demonstrated a 1.23 
(95% 1.06 to 1.44, model 2) times higher likelihood for severe sarcopenia compared to 
participants in the lowest tertile of ASTP. The significance of this relationship, however, 
disappeared after the adjustment for chronic health conditions (model 3). There were no 
significant associations across tertiles of long MVPA bouts (≥10 minutes) and sedentary 
breaks with severe sarcopenia.   
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Table 23: Dose-response associations of patterns of physical behavior metrics with 
sarcopenia status 
Dose-response associations of short MVPA bouts (<10 minutes) duration tertiles with sarcopenia status 
  MVPA <10 minute bout (min/day) 
  First Tertile Second Tertile Third Tertile 
n 30 28 29 
MVPA <10 minute bout, mean (SD) 2.3 (0.7) 5.0 (1.3) 16.9 (10.2) 
Probable sarcopenia (yes/no)       
Model 1 Ref 0.91 (0.71 to 1.17) 0.80 (0.62 to 1.03) 
Model 2 Ref 0.89 (0.69 to 1.14) 0.80 (0.62 to 1.02) 
Model 3 Ref 0.90 (0.70 to 1.16) 0.81 (0.63 to 1.05) 
Confirmed sarcopenia (yes/no)       
Model 1 Ref 1.01 (0.81 to 1.25) 0.81 (0.65 to 1.00) 
Model 2 Ref 0.97 (0.79 to 1.19) 0.81 (0.66 to 0.99) 
Model 3 Ref 0.98 (0.80 to 1.21) 0.82 (0.67 to 1.01) 
Severe sarcopenia (yes/no)       
Model 1 Ref 0.92 (0.79 to 1.07) 0.81 (0.69 to 0.95) 
Model 2 Ref 0.90 (0.77 to 1.05) 0.81 (0.69 to 0.94) 
Model 3 Ref 0.92 (0.79 to 1.08) 0.82 (0.71 to 0.96) 
    
Dose-response associations of long MVPA bouts (≥10 minutes) duration groups with sarcopenia status 
  MVPA ≥10 minute bout (min/day)  
  No ≥10 minute bouts ≥10 minute bouts  
n 76 11  
MVPA ≥10 minute bout, mean (SD) 0.0 (0.0) 8.8 (6.7)  
Probable sarcopenia (yes/no)      
Model 1 Ref 0.63 (0.47 to 0.85)  
Model 2 Ref 0.65 (0.49 to 0.87)  
Model 3 Ref 0.65 (0.47 to 0.89)  
Confirmed sarcopenia (yes/no)      
Model 1 Ref 0.77 (0.59 to 1.00)  
Model 2 Ref 0.81 (0.63 to 1.04)  
Model 3 Ref 0.87 (0.67 to 1.14)  
Severe sarcopenia (yes/no)      
Model 1 Ref 0.90 (0.74 to 1.09)  
Model 2 Ref 0.02 (0.76 to 1.11)  
Model 3 Ref 0.93 (0.76 to 1.14)  
    
Dose-response associations of number of sedentary breaks tertiles with sarcopenia status 
  Number of sedentary breaks (no. of breaks/day) 
  First Tertile Second Tertile Third Tertile 
n 29 29 29 
Sedentary breaks, mean (SD) 51.8 (12.7) 71.6 (3.5) 87.8 (6.6) 
Probable sarcopenia (yes/no)       
Model 1 Ref 1.04 (0.81 to 1.33) 0.90 (0.70 to 1.15) 
Model 2 Ref 1.04 (0.81 to 1.34) 0.92 (0.72 to 1.18) 
Model 3 Ref 1.06 (0.82 to 1.36) 0.94 (0.72 to 1.23) 
Confirmed sarcopenia (yes/no)       
Model 1 Ref 1.03 (0.83 to 1.27) 0.81 (0.65 to 1.00) 
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Model 2 Ref 1.03 (0.84 to 1.26) 0.82 (0.67 to 1.01) 
Model 3 Ref 1.06 (0.87 to 1.29) 0.82 (0.67 to 1.02) 
Severe sarcopenia (yes/no)       
Model 1 Ref 0.96 (0.82 to 1.13) 0.90 (0.77 to 1.05) 
Model 2 Ref 0.96 (0.82 to 1.13) 0.91 (0.77 to 1.07) 
Model 3 Ref 0.97 (0.83 to 1.14) 0.94 (0.79 to 1.11) 
    
Dose-response associations of ASTP tertiles with sarcopenia status 
  ASTP 
  First Tertile Second Tertile Third Tertile 
n 29 29 29 
ASTP, mean (SD) 0.37 (0.05) 0.48 (0.03) 0.61 (0.08) 
Probable sarcopenia (yes/no)       
Model 1 Ref 1.23 (0.97 to 1.57) 1.16 (0.91 to 1.48) 
Model 2 Ref 1.21 (0.95 to 1.54) 1.12 (0.88 to 1.43) 
Model 3 Ref 1.19 (0.93 to 1.53) 1.04 (0.79 to 1.37) 
Confirmed sarcopenia (yes/no)       
Model 1 Ref 1.24 (1.01 to 1.52) 1.27 (1.03 to 1.57) 
Model 2 Ref 1.20 (0.98 to 1.46) 1.20 (0.98 to 1.48) 
Model 3 Ref 1.17 (0.96 to 1.44) 1.11 (0.89 to 1.39) 
Severe sarcopenia (yes/no)       
Model 1 Ref 1.08 (0.93 to 1.25) 1.26 (1.08 to 1.26) 
Model 2 Ref 1.07 (0.92 to 1.24) 1.23 (1.06 to 1.44) 
Model 3 Ref 1.06 (0.91 to 1.23) 1.18 (1.00 to 1.40) 
Notes: Bold values are significant. Probable or confirmed sarcopenia will be defined using low upper limb 
muscle strength evaluated by a calibrated handgrip dynamometer (grip strength: <27 kg for men and <16 kg 
for women), low muscle mass tested by a dual-energy X-ray absorptiometry (appendicular skeletal muscle 
mass: <20 kg for men and <15 kg for women), and low physical performance assessed by a 20-m usual 
walking speed test (gait speed: ≤0.8 m/s). The active-to-sedentary transition probability index is calculated by 
dividing the total number of breaks in sedentary behavior with the sum of minutes spent in physical activity. 
Abbreviations: ASTP: active-to-sedentary transition probability; MVPA: moderate to vigorous physical 
activity; OR (95% CI): odds ratio (95% confidence interval). 
Model 1: adjusted for age, gender, race, education, accelerometer wear time 
Model 2: model 1 + lifestyle factors (BMI, smoking status) 
Model 3: model 2 + chronic health conditions (diabetes, hypertension, history of cardiovascular disease, 






The aim of this study was to gain a better understanding regarding the 
associations of various accelerometer-determined physical behavior metrics with 
sarcopenia status and its components among oldest-old adults. Cross-sectional data from 
the Health ABC cohort study of community-dwelling oldest-old adults with a mean age 
of 88.2 (2.5) years helps address our research aims. As described in Chapter 3, we created 
two different samples for this secondary analysis. The primary sample with a total of 145 
participants focused on the associations of physical behavior metrics with EWGSOP2 
defined probable sarcopenia and handgrip strength. Moreover, the subsample with 87 
participants looked at the associations of physical behavior metrics with EWGSOP2 
defined probable, confirmed, and severe sarcopenia as well as their related components 
including handgrip strength, appendicular lean mass, and gait speed. The findings of this 
study correspond with our hypotheses by highlighting that higher volumes of MVPA, 
regardless of its accumulation in short MVPA bouts (<10 minutes) or long MVPA bouts 
(≥10 minutes), are associated with lower odds of EWGSOP2 defined sarcopenia and 
better sarcopenia-relevant indicators among oldest-old adults. 
5.1 Associations of Physical Behavior Volume Metrics with Sarcopenia 
The first main subject of discussion represents the interpretation of our study 
findings regarding the associations of physical behavior volume metrics, including total 
activity counts, total MVPA, total LIPA, and total SB, with sarcopenia and its 
components in due consideration of previous research.  
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First, there were no significant associations of total activity counts with probable, 
confirmed, or severe sarcopenia in our study. These results are not in line with prior 
examinations which demonstrated that objectively measured total activity counts are 
related with sarcopenia and its components.64,90 Westbury et al.90 and Sanchez-Sanchez et 
al.64 observed that higher total activity counts were associated with lower odds of 
EWGSOP defined sarcopenia and FNIH defined sarcopenia, respectively. The variety of 
used sarcopenic definitions among previous analyses hinders the comparability of 
provided study outcomes.20,21 In this context, dissimilarities exist between the original 
EWGSOP definition and the revised EWGSOP2 definition in terms of their different cut-
off values.22 For instance, while EWGSOP identifies low handgrip strength as <30 kg for 
men and <20 kg for women, the EWGSOP2 algorithm diagnoses low handgrip strength 
with cut-off points of <27 kg for men and <16 kg for women which leads to considerable 
dissimilarities regarding the sarcopenia prevalence rates.131 
Furthermore, our study outcomes indicate that accelerometer-determined MVPA 
was significantly associated with a lower likelihood of sarcopenia which is in agreement 
with previous research.64,66 In this regard, each 5 minutes more per day of MVPA was 
related with 27% lower odds for a probable sarcopenic condition among oldest-old 
adults. Despite non-significant associations of total MVPA volumes with sarcopenic 
conditions in the subsample, we observed a trend that each 5 minutes more per day in 
MVPA was related with lower odds of probable and confirmed sarcopenia. The 
attenuated significance in the subsample might be caused by the reduced sample size and 
the related loss of statistical power. Non-significant findings regarding the associations of 
accelerometer-assessed MVPA with sarcopenia are not uncommon. For instance, studies 
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from Aggio et al.96 and Westbury et al.90 were also not able to identify any significant 
association between objectively measured MVPA and EWGSOP defined sarcopenia. 
Likewise, results of the dose-response analysis indicated that the daily volume of MVPA 
should exceed 10 minutes in order to significantly lower the odds of probable sarcopenia. 
These findings suggest that engaging more time in MVPA may be associated with lower 
odds of sarcopenia among oldest-old adults. 
A non-significant relationship between LIPA and probable sarcopenia was 
illustrated among our primary sample. However, after applying the full EWGSOP2 
algorithm to determine the diagnostic state of sarcopenia,18 there were associations with 
the likelihood of confirmed and severe sarcopenia. Participants who engaged more time 
in LIPA had 18% and 13% lower odds of confirmed and severe sarcopenia, respectively. 
In this context, a recent randomized controlled trial study with 28 older women reported 
that 8 weeks of SB displacement with LIPA (45-50 minutes daily) significantly improved 
handgrip strength and gait speed.132 This is a promising finding since LIPA can be better 
sustained than MVPA by older adults.132 Consequently, LIPA might be an encouraging 
concept for future health guidelines to improve or maintain musculoskeletal health 
among oldest-old adults.  
Several studies have reported that accelerometer-determined SB levels are not 
related with the prevalence of sarcopenia among older adults.66,96,115 In our sample of 
oldest-old adults, spending 60 minutes more per day in SB was associated with a 2.10- 
and 3.79-times higher likelihood for confirmed sarcopenia and severe sarcopenia. More 
research is needed to clarify the influence of SB on musculoskeletal health in oldest-old 
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adults which might contribute crucial information for future health guidelines.111 Overall, 
high levels of SB may be associated with lower odds of confirmed and severe sarcopenia. 
With the focus on sarcopenic components, our study outcomes are in agreement 
with previous research, showing that higher total activity counts,64,90 higher MVPA,64,96 
and higher LIPA96 were associated with better gait speed. On the other hand, higher SB 
was associated with worse gait speed which is also in line with prior studies.91,96 
Modifications of physical behavior volume metrics by spending more time in active and 
less time in sedentary behavior might help enhance the physical performance of oldest-
old adults. These performance improvements may provide a vital contribution for better 
muscle health which is a key factor for independence and thus a higher quality of life 
among the oldest-old adult population.133,134  
5.2 Associations of Physical Behavior Pattern Metrics with Sarcopenia 
The second main subject of discussion represents the interpretation of our study 
findings regarding the associations of physical behavior pattern metrics, including short 
MVPA bout duration (<10 minutes), long MVPA bout duration (≥10 minutes), total 
number of sedentary breaks, and ASTP, with sarcopenia and its components in due 
consideration of prior examinations.  
Recent studies have shown that the accumulation of MVPA levels with short 
bouts of less than 10 minutes contribute to the improvement of various health-related 
outcomes.62,63 To the best of our knowledge, this is the first study to look at the 
association of accelerometer-determined short MVPA bouts with sarcopenia status and its 
components. Interestingly, our study outcomes indicated that higher accumulated time 
spent in short MVPA bouts was associated with lower odds of any sarcopenic condition, 
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including probable, confirmed, and severe sarcopenia. In this context, Hrubeniuk et al.135 
reported that each minute spent in MVPA led to significantly better physical function 
among older adults. These findings underscore the potentially positive impact of short 
MVPA bouts on sarcopenic status among oldest-old adults. Encouraging oldest-old adults 
to accumulate high levels of MVPA without the need to sustain bouts lasting longer than 
10 minutes might be beneficially associated with muscle-related health.  
Study results from Scott et al.66 indicated that the accumulated time spent in 
MVPA bouts longer than 10 minutes was significantly associated with a lower likelihood 
of probable or confirmed sarcopenia.66 This is congruent with the outcomes provided in 
our primary sample since each 5 minutes more time engaged in long MVPA bouts 
indicated 69% lower odds for a probable sarcopenic state. Findings of the dose-response 
analysis exhibited that participants who spent at least some time in long MVPA bouts had 
a lower likelihood for a probable sarcopenic condition compared to individuals who 
engaged zero minutes in long MVPA bouts. However, only a small fraction of people at 
this age might be able to engage in long MVPA bouts. Just 21(14.5%) participants in the 
primary sample and a total of 11 (12.6%) participants in the subsample provided at least 
some minutes in MVPA bouts lasting longer than 10 minutes. A low frequency of long 
MVPA bouts was expected due to the advanced age of included individuals. 
Unfortunately, the absence of a normal distribution and the high number of participants 
with zero minutes spent in long MVPA bouts resulted in a limited ability to statistically 
compute binomial logistic regressions in the subsample. This also restricts our capability 
to directly compare shorter vs. longer bouts of MVPA in this sample, since so few 
individuals accumulated MVPA in longer bouts. Recent evidence reported that older 
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adults prefer to participate in short MVPA bouts compared to long MVPA bouts which 
might indicate an increased tolerance to accumulate high levels of MVPA minutes via 
short sporadic bouts.135 In addition, Menai et al. (2017) reported that higher time spent in 
short MVPA bouts was similarly associated with successful aging (defined as a 
combination of better cognitive, motor, and respiratory functions as well as absence of 
major chronic diseases) as when MVPA was accumulated in prolonged bouts among 
older adults. Consequently, short MVPA bouts might be a feasible and efficient 
alternative to maintain or improve muscle health among oldest-old adults.  
We did not find any significant association of sedentary breaks with probable, 
confirmed, or severe sarcopenia. Prior investigations have also indicated no relationship 
between the total number of objectively measured sedentary breaks and sarcopenia.96,115 
Interestingly, higher numbers of daily sedentary breaks were associated with higher 
appendicular lean mass which is not in accordance with the results from Aggio et al.96 
who found no association. Frequent interruptions of SB might lead to a multitude of 
additional contractions throughout the day which in turn may cause alterations in the 
muscle expression of genes responsible for cellular development, growth and 
proliferation, and carbohydrate metabolism.136,137 This physiological process might 
benefit the musculoskeletal health among older adults. However, epidemiological 
research has provided inconclusive evidence with respect to the relationship between 
sedentary breaks and muscle mass.111 
The analysis of the activity fragmentation in older adults via the active-to-
sedentary transition probability (ASTP) index is a promising concept for quantifying 
patterns of activity, particularly in aging populations.48 As we age, we might expect a 
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dramatic change of activity profiles due to functional declines.48 In this context, PA 
patterns frequently become more fragmented among older adults due to emerging 
difficulties in sustaining PA bouts for a longer period of time.50 Fragmented daily PA 
patterns, characterized by a higher ASTP index, have been linked with various 
detrimental health outcomes including poor physical performance,48 greater fatigability,50 
cognitive impairment,51 and a higher mortality risk in the older adult population.49 This is 
the first study we are aware of to identify the association of accelerometer-determined 
ASTP with sarcopenia status and its components. Outcomes of the subsample 
demonstrated that each 0.1 higher ASTP was linked with 2.90 times greater odds for a 
severe sarcopenia diagnosis. Focusing on individual components of sarcopenia, higher 
ASTP showed an association with lower gait speed in both genders. Similar findings 
were reported by Schrack et al.48, where higher ASTP was also related with worse gait 
speed performance among older adults. Therefore, oldest-old adults with less fragmented 
activity patterns might demonstrate associations with a lower likelihood of severe 
sarcopenia and better gait speed. Comparable outcomes were provided by Chastin et 
al.138, who showed a significant relationship between less fragmented activity patterns 
and better muscle quality among older adults. In this context, the ASTP index might be a 
useful marker for the assessment of accelerated biological aging51 and thus a predictor for 
the onset and/or severity of sarcopenia. ASTP does not address differences in total 
volume of PA. For instance, an individual who obtains 100 minutes of activity with 10 
breaks would provide the same ASTP score as an individual who obtains 10 minutes of 
activity with 1 break (ASTP = 0.1 for both). Therefore, ASTP may better represent 
physical function than levels of PA. Activity fragmentation in which older adults need to 
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break up activity more often might be an early sign for poorer physical function. 
Furthermore, we should note that the utilization of activity fragmentation calculations 
may be most applicable in old adult populations rather than young adult populations due 
to the presence of functional declines with advancing age.48 Consequently, accelerometer 
determined activity fragmentation metrics such as the ASTP index might serve as a 
valuable indicator of functional declines among older adults.  
5.3 Strengths and Limitations 
This study benefits from a comprehensive data set among a sample of the oldest-
old adult population which includes measures of demographic and lifestyle factors, 
chronic health conditions, muscle strength, muscle mass, physical performance, and 
accelerometry. Owing to the availability of ActiGraph GT3X+ accelerometer data, we 
were able to analyze the association of various physical behavior metrics with 
EWGSOP2 defined sarcopenia and its determinants. This approach allowed us the 
investigation of relationships with clinically relevant sarcopenia definitions as well as the 
underlying factors of handgrip strength, appendicular lean mass, and gait speed. Tri-axial 
accelerometry is considered a relatively valid and reliable method of evaluating free-
living behavior which provides a detailed estimation of activities in terms of their volume 
and intensity.58 Accelerometer data are provided by a demographically diverse 
community-dwelling population with a high mean age of 88.2 (2.5) years. Another 
strength of our study is the employment of the EWGSOP2 sarcopenia definition which is 
widely accepted and endorsed by a range of international scientific societies.18 Moreover, 
we utilized DXA-scan data in order to assess muscle mass in our sample. DXA provides 
more accurate and reliable estimations of muscle mass compared to other evaluation 
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methods such as anthropometric measures or BIA.18 We also created 3 different models 
with the purpose to adjust for several key covariates including various demographic 
factors plus accelerometer wear time (model 1), lifestyle factors (model 2), and chronic 
health conditions (model 3). All these covariates have shown connections with sarcopenic 
conditions and their components. In addition, this study provided novel insights into the 
associations of short MVPA bouts (<10 minutes) and ASTP with EWGSOP2 defined 
sarcopenia and its components.  
Our analysis has several limitations. Due to the cross-sectional study design, we 
cannot infer causalities regarding the associations of physical behavior metrics with 
sarcopenic conditions and their determinants. Despite our hypothesis that higher levels of 
intense PA levels are associated with lower sarcopenia-relevant indicators, there is also 
the possibility of a reverse causality in which diminished muscle strength, muscle mass, 
or physical performance induce lower volumes and intensities of PA. In addition, we had 
to remove all Pittsburgh-dwelling individuals from our subsample because of the 
unavailability of DXA-scan data. Removing those participants considerably reduced the 
statistical power of our subsample analysis. Furthermore, there was a low number of 
oldest-old adults with long MVPA bouts which limited our ability to investigate 
associations of long MVPA bouts with sarcopenia and its components. Although we 
adjusted for a variety of covariates, there remains a possibility of residual confounding. 
For example, potential covariates such as malnutrition or osteoporosis were not collected 
at year 16 and therefore not included in our study. Unfortunately, despite being the most 
rapidly increasing population,7 specified accelerometer cut-off points to determine PA 
intensities among oldest-old adults are not available in the current literature. The absence 
 
101 
of an accelerometer-specific standardized protocol for the oldest-old adult population is 
considered a substantial limitation since physical function decreases at an annual rate of 
approximately 4% after the age of 65 years.139 Due to age-related physical declines and 
related alterations of walking patterns, an oldest-old adult at the age of 85 years might 
show a higher energy expenditure for the same activity compared to an older adult at the 
age of 65 years.140 Consequently, a lower cut-point for MVPA than that provided by 
Copeland et al.130 may be appropriate for oldest-old adults in order to obtain more 
accurate evaluations of their physical behavior metrics. We should also note that the 
limited ability of ActiGraphs to distinguish between LIPA and SB might lead to a 
misclassification of behavioral activities.141,142 In this context, standing activities such as 
washing dishes or folding laundry are often disregarded by accelerometers.141,142 Hip-
worn ActiGraphs also present difficulties in capturing data of upper body movements 
which have demonstrated strong associations with sarcopenia and its components.35,142,143 
Furthermore, because participants were instructed to remove the accelerometers during 
water-related activities, data of muscle-health-promoting aquatic exercises were also 
disregarded in our study.144 Nevertheless, missing information about these activities may 
not pose a major limitation for our analysis since previous research has shown that the 
vast majority of older adults prefer to spend most of their active time in ambulatory 
activities such as walking which can be estimated with a relatively high accuracy by hip-





Modifiable characteristics of physical behavior offer promising opportunities to 
maintain or improve the musculoskeletal health in oldest-old adults. Our study findings 
contribute valuable knowledge to geriatric research by identifying cross-sectional 
associations of accelerometer-determined various physical behavior metrics with 
EWGSOP2 defined sarcopenia and its components among the oldest-old adult 
population. Higher volumes of MVPA, regardless of its pattern of accumulation, 
demonstrated associations with lower odds of probable sarcopenia in our primary sample. 
Consequently, accruing MVPA in long bouts might not be necessary to lower the 
likelihood of a probable sarcopenia diagnosis. This is an important finding for an 
increasingly aging population which seems to have difficulties sustaining prolonged 
MVPA bouts of at least 10 minutes.  
Following the application of the full EWGSOP2 definition in the subsample, 
higher volumes of LIPA demonstrated associations with a lower likelihood of confirmed 
and severe sarcopenia. Additionally, greater odds of confirmed and severe sarcopenia 
were related with higher volumes of SB. This study also observed novel evidence that 
higher fragmented activity patterns were associated with severe sarcopenia and lower gait 
speed, indicating that activity fragmentation assessments might serve as a valuable index 
to detect severely deteriorated musculoskeletal health among the oldest-old adult 
population. The results of the dose-response analyses illustrated that most physical 
behavior metrics show significant associations with sarcopenic status in the highest tertile 
or group, while almost no significant links were seen among the second tertile or group. 
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This may provide the opportunity to define specific doses of daily physical behavior 
which might help lower the odds of sarcopenia in the oldest-old adult population. With 
focus on individual components of EWGSOP2 defined sarcopenia, our findings suggest 
that especially higher levels of PA, including total activity counts, MVPA, and LIPA, 
were associated with better gait speed. Therefore, physical function among oldest-old 
adults might be better preserved when overall greater volumes of PA are realized.  
Based on the findings of our study, we can conclude that patterns of accumulated 
MVPA had an equally strong association with sarcopenia as the total volume of MVPA, 
highlighting the fact that short sporadic MVPA bouts might help maintain or improve 
musculoskeletal health in oldest-old adults. Overall, short MVPA bouts should gain more 
attention in geriatric research since they may provide information that can help design 
feasible and muscle-health promoting PA recommendations for the oldest-old adult 
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